Intellect Neurosciences 10-K 14 Oct 14 2014 FY Annual report Financial data

Document_And_Entity_Informatio

Document And Entity Information (USD $)	12 Months Ended
	Jun. 30, 2014	Oct. 14, 2014	Dec. 31, 2013
Document Information [Line Items]	'	'	'
Entity Registrant Name	'Intellect Neurosciences, Inc.	'	'
Entity Central Index Key	'0001337905	'	'
Current Fiscal Year End Date	'--06-30	'	'
Entity Filer Category	'Smaller Reporting Company	'	'
Trading Symbol	'ILNS	'	'
Entity Common Stock, Shares Outstanding	'	623,512,076	'
Document Type	'10-K	'	'
Amendment Flag	'false	'	'
Document Period End Date	30-Jun-14	'	'
Document Fiscal Period Focus	'FY	'	'
Document Fiscal Year Focus	'2014	'	'
Entity Well-known Seasoned Issuer	'No	'	'
Entity Voluntary Filers	'No	'	'
Entity Current Reporting Status	'No	'	'
Entity Public Float	'	'	$1,588,578

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Jun. 30, 2014	Jun. 30, 2013
Current assets:	'	'
Cash and cash equivalents	$0	$5,138
Total current assets	0	5,138
Security deposits	2,250	4,715
Total Assets	2,250	9,853
Current Liabilities:	'	'
Accounts payable and accrued expenses	2,682,272	2,487,410
Accrued interest - convertible promissory notes	1,047,383	482,298
Derivative instruments	7,209,188	3,833,457
Preferred stock liability	'	172,874
Preferred stock dividend payable	15,032,543	5,350,503
Convertible promissory notes - current, net of debt discount of $167,408 and $297,408, respectively	1,464,452	645,040
Total Current liabilities	27,435,838	12,971,582
Long Term Debt	'	'
Convertible promissory notes - current, net of debt discount of $167,408 and $297,408, respectively	727,203	586,697
Total Liabilities	28,163,041	13,558,279
Capital deficiency:	'	'
Common stock, par value $0.001 per share, 2,000,000,000 shares authorized; 409,512,076 and 209,015,899 issued and outstanding at June 30, 2014, and June 30, 2013, respectively	409,512	209,016
Additional paid in capital	70,373,087	70,134,476
Accumulated Deficit	-98,943,510	-83,891,966
Total Capital Deficiency	-28,160,791	-13,548,426
Total Liabilities and Capital Deficiency	2,250	9,853
Series B Convertible Preferred Stock [Member]	'	'
Capital deficiency:	'	'
Convertible Preferred stock	75	0
Series C Convertible Preferred Stock [Member]	'	'
Capital deficiency:	'	'
Convertible Preferred stock	21	24
Series D Convertible Preferred Stock [Member]	'	'
Capital deficiency:	'	'
Convertible Preferred stock	3	3
Series E Convertible Preferred Stock [Member]	'	'
Capital deficiency:	'	'
Convertible Preferred stock	$21	$21

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets [Parenthetical] (USD $)	Jun. 30, 2014	Jun. 30, 2013
Common stock, par value (in dollars per share)	$0.00	$0.00
Common stock, shares authorized	2,000,000,000	2,000,000,000
Common stock, shares issued	409,512,076	409,512,076
Common stock, shares outstanding	209,015,899	209,015,899
Convertible Notes Payable Current [Member]	'	'
Debt Instrument, Unamortized Discount	$167,408	$297,408
Convertible Notes Payable Noncurrent [Member]	'	'
Debt Instrument, Unamortized Discount	936,297	840,814
Series B Convertible Preferred Stock [Member]	'	'
Preferred stock, par value (in dollars per share)	$0.00	$0.00
Preferred stock, shares authorized	459,309	459,309
Preferred stock, shares issued	75,751	75,751
Preferred Stock, Shares Outstanding	75,751	75,751
Preferred stock, liquidated (in dollars)	1,325,644	1,325,644
Series C Convertible Preferred Stock [Member]	'	'
Preferred stock, par value (in dollars per share)	$0.00	$0.00
Preferred stock, shares authorized	25,000	25,000
Preferred stock, shares issued	20,977	20,977
Preferred Stock, Shares Outstanding	23,525	23,525
Preferred stock, liquidated (in dollars)	20,977,000	23,525,000
Series D Convertible Preferred Stock [Member]	'	'
Preferred stock, par value (in dollars per share)	$0.00	$0.00
Preferred stock, shares authorized	25,000	25,000
Preferred stock, shares issued	2,533	2,533
Preferred Stock, Shares Outstanding	3,208	3,208
Preferred stock, liquidated (in dollars)	2,533,000	3,208,000
Series E Convertible Preferred Stock [Member]	'	'
Preferred stock, par value (in dollars per share)	$0.00	$0.00
Preferred stock, shares authorized	25,000	25,000
Preferred stock, shares issued	20,805	20,805
Preferred Stock, Shares Outstanding	20,805	20,805
Preferred stock, liquidated (in dollars)	$20,805,000	$20,805,000

Consolidated_Statements_of_Ope

Consolidated Statements of Operations (USD $)	12 Months Ended
	Jun. 30, 2014	Jun. 30, 2013
Revenues:	'	'
License fees	$0	$0
Total revenue	0	0
Costs and Expenses:	'	'
Research and development	82,620	222,300
General and administrative	1,054,620	4,125,386
Total cost and expenses	1,137,240	4,347,686
Loss from operations	-1,137,240	-4,347,686
Other income/(expenses):	'	'
Interest expense	-13,168,563	-6,681,908
Changes in fair value of derivative instruments	-745,741	2,549,892
Total other income/(expense):	-13,914,304	-4,132,016
Net loss	-15,051,544	-8,479,702
Deemed preferred stock dividend	'	700,000
Net loss allocable to common shareholders	($15,051,544)	($9,179,702)
Basic and diluted loss per share (in dollars per share)	($0.05)	($0.06)
Weighted average number of shares outstanding:	'	'
Basic and diluted (in shares)	319,751,808	136,468,981

Consolidated_Statement_of_Chan

Consolidated Statement of Changes in Capital Deficiency [Equity] (USD $)	Total	Series C Preferred Stock [Member]	Series D Preferred Stock [Member]	Series E Preferred Stock [Member]	Series B Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Deficit accumulated during the development stage (Member)
Balance at Jun. 30, 2012	($11,079,928)	$24	$0	$0	$0	$100,240	$62,956,264	($74,136,456)
Balance (in shares) at Jun. 30, 2012	'	24,435	0	0	0	100,240,020	'	'
Stock based compensation	192,500	'	'	'	'	17,250	175,250	'
Stock based compensation (in shares)	'	'	'	'	'	17,250,000	'	'
Conversion of accrued Series C interest to Series C shares	840,000	1	'	'	0	'	839,999	'
Conversion of accrued Series C interest to Series C shares (in shares)	'	840	'	'	0	'	'	'
Cashless exercise of Warrants	411,615	'	'	'	'	29,526	382,089	'
Cashless exercise of Warrants (in shares)	'	'	'	'	'	29,525,879	'	'
Issuance of Series D preferred stock	2,442,897	'	4	'	'	'	2,442,893	'
Issuance of Series D preferred stock (in shares)	'	'	4,458	'	'	'	'	'
Issuance of Series E preferred stock	2,700,000	'	'	21	'	'	2,699,979	'
Issuance of Series E preferred stock (in shares)	'	'	'	20,805	'	'	'	'
Conversion of Series C preferred stock into common stock	0	-1	'	'	0	37,000	-36,999	'
Conversion of Series C preferred stock into common stock (in shares)	'	-1,750	'	'	0	37,000,000	'	'
Conversion of Series D preferred stock into common stock	0	'	-1	'	'	25,000	-24,999	'
Conversion of Series D preferred stock into common stock (in shares)	'	'	-1,250	'	'	25,000,000	'	'
Deemed Preferred Stock Dividend	700,000	'	'	'	'	'	700,000	'
Net income (loss) for the period	-8,479,702	'	'	'	'	'	'	-9,755,510
Balance at Jun. 30, 2013	-13,548,426	24	3	21	0	209,016	70,134,476	-83,891,966
Balance (in shares) at Jun. 30, 2013	'	23,525	3,208	20,805	0	209,015,899	'	'
Stock based compensation	307,250	'	'	'	'	39,000	268,250	'
Stock based compensation (in shares)	'	'	'	'	'	39,000,000	'	'
Conversion of convertible notes to common stock	131,929	'	'	'	'	13,183	118,746	'
Conversion of convertible notes to common stock (in shares)	'	'	'	'	'	13,183,055	'	'
Reclassification of Series B preferred	0	'	'	'	75	'	-75	'
Reclassification of Series B preferred (in shares)	'	'	'	'	75,751	'	'	'
Conversion of Preferred stock to common stock	0	-3	0	'	'	148,313	-148,310	'
Conversion of Preferred stock to common stock (in shares)	'	-2,548	-675	'	'	148,313,122	'	'
Net income (loss) for the period	-15,051,544	'	'	'	'	'	'	-15,051,544
Balance at Jun. 30, 2014	($28,160,791)	$21	$3	$21	$75	$409,512	$70,373,087	($98,943,510)
Balance (in shares) at Jun. 30, 2014	'	20,977	2,533	20,805	75,751	409,512,076	'	'

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	12 Months Ended
	Jun. 30, 2014	Jun. 30, 2013
CASH FLOWS FROM OPERATING ACTIVITIES:	'	'
Net loss	($15,051,544)	($9,179,702)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'
Change in fair value of derivative instruments	745,741	-1,974,084
Stock and warrant based compensation	307,250	3,799,786
Non-cash interest expense	13,168,588	6,681,908
Change in assets and liabilities	'	'
Prepaid expenses	'	19,585
Security deposits	2,465	'
Accounts payable and accrued expenses	194,862	97,646
Net cash used in operating activities	-632,638	-1,130,669
CASH FLOWS FROM FINANCING ACTIVITIES:	'	'
Proceeds form issuance of convertible notes	637,500	1,166,000
Repayments of convertible notes	-10,000	-32,500
Net cash provided by financing activities	627,500	1,133,500
NET INCREASE (DECREASE) IN CASH	-5,138	2,831
CASH - BEGINNING OF YEAR	5,138	2,307
CASH - END OF YEAR	0	5,138
SUPPLEMENTAL CASH FLOW INFORMATION:	'	'
Interest	0	0
Taxes	0	0
Non-cash financing activities	'	'
Conversion of convertible notes and interest to common stock	131,929	0
Conversion of preferred stock to common stock	0	62,000
Debt discount recognized as derivative liability	637,500	890,697
Deemed preferred stock dividend form beneficial conversion feature	0	700,000
Issuance of warrants for repayment of accrued expenses	0	560,000
Cashless exercise of Warrants for Common Stock	$0	$411,615

Business_Description_and_Going

Business Description and Going Concern	12 Months Ended
	Jun. 30, 2014
Organization, Consolidation and Presentation Of Financial Statements [Abstract]	'
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	'
	Note 1. Business Description and Going Concern
	Intellect Neurosciences, Inc., a Delaware corporation, (“Intellect”, “our”, “us”, “we” or the “Company” refer to Intellect Neurosciences, Inc. and its subsidiary) is a biopharmaceutical company, which together with its subsidiary, Intellect Neurosciences, USA, Inc. (“Intellect USA”), is engaged in the discovery and development of disease-modifying therapeutic agents for the treatment and prevention of neurodegenerative conditions, collectively known as proteinopathies, which include Alzheimer’s (“AD”), Parkinson’s and Huntington disease. Since our inception in 2005, we have devoted substantially all of our efforts and resources to research and development activities and advancing our patent estate. We operate under a single segment.   We have had no product sales from inception through June 30, 2014 but we have received $10,516,667 in license fees from inception through June 30, 2014. Our losses from operations have been funded primarily with the proceeds of equity and debt financings and fees from license arrangements.
	Our core business strategy is to build a portfolio of compounds with the potential to treat or prevent neurodegenerative diseases, develop each to pre-determined milestones, and license them to pharmaceutical companies for advanced development and commercialization. To supplement our own work, we intend to license promising novel technologies and early stage compounds from academia and other biotechnology companies. We intend to obtain revenues from licensing fees, milestone payments, development fees, royalties and/or sales related to the use of our drug candidates or intellectual property for specific therapeutic indications or applications.
	As of June 30, 2014, we had no self-developed or licensed products approved for sale by the U.S. Food and Drug Administration (“FDA”). There can be no assurance that our research and development efforts will be successful, that any products developed by any of our licensees will obtain necessary government regulatory approval or that any approved products will be commercially viable. In addition, we operate in an environment of rapid change in technology and are dependent upon the continued services of our current employees, consultants and subcontractors.
	These consolidated financial statements are presented on the basis that we will continue as a going concern.  The going concern concept contemplates the realization of assets and satisfaction of liabilities in the normal course of business.  Since our inception in 2005, we have generated losses from operations and we anticipate that we will continue to generate significant losses from operations for the foreseeable future. As of June 30, 2014, we had negative working capital of $(27,435,588) and our accumulated deficit was $98,943,510. We have primarily generated a loss from operations. The Company had a loss from operations of $1,137,240 for the year ended June 30, 2014 compared to an operating loss of $4,347,686 for the year ended June 30, 2013.  Our cash used in operations was $632,638 and $1,130,669 for the years ended June 30, 2014 and 2013, respectively. Our capital deficiency was $28,160,791 and $13,548,426 as of June 30, 2014 and 2013, respectively
	We have limited capital resources and operations since inception have been funded with the proceeds from equity and debt financings and license fee arrangements.  As of June 30, 2014, we had zero cash or cash equivalents. We anticipate that our existing capital resources will enable us to continue operations for the next six months. If we fail to raise additional capital or obtain substantial cash inflows from existing or potential partners within the next few months, we may be forced to cease operations. The financial statements do not include any adjustments that might result from their uncertainty.
	On July 25, 2014, we entered into a stock purchase agreement with certain accredited investors whereby we issued to the Investors an aggregate 1,200 shares of Series F Convertible Preferred Stock and warrants to purchase an aggregate of 2.4 billion shares of common stock, par value $0.001 per share of the Company in exchange for gross proceeds of $1,200,000  (see Note 12, Subsequent Events).
	We anticipate that our existing capital resources will enable us to continue operations for the next six months. If we fail to raise additional capital or obtain substantial cash inflows from existing or potential partners within the next month, we may be forced to cease operations. We cannot assure you that financing will be available in a timely manner, on favorable terms or at all.
	Business Strategy
	Our core business strategy is to build a portfolio of compounds with the potential to treat or prevent neurodegenerative diseases, develop each compound to pre-determined milestones, and license the compounds to pharmaceutical companies for advanced development and commercialization. We intend to obtain revenues from licensing fees, milestone payments, development fees, royalties and/or sales related to the use of our drug candidates or intellectual property for specific therapeutic indications or applications.
	One of our key assets is our license agreement with Shire Plc (“Shire”) regarding OX1, a small molecule, multi-modal antioxidant. We completed preclinical and human safety trials, and then licensed the program to ViroPharma Inc. for development of a drug to treat Friedreich's Ataxia and other neurodegenerative diseases. In January 2014, ViroPharma merged with Shire. We could receive up to $120 million in milestone payments from Shire and significant royalties from sales if the resulting drug product is approved for sale by the FDA. There can be no assurance that we will receive such milestone payments or royalties. In addition, we have entered into two non-exclusive license agreements and one option agreement with major global pharmaceutical companies with respect to our ANTISENILIN patent estate.
	OUT-LICENSED PROGRAMS:
		·	OX1 – Licensed to ViroPharma, Inc.
	OX1 is an orally-administered, brain-penetrating, naturally-occurring copper-binding small molecule, which has the potential to treat various neurodegenerative diseases such as Friedreich's Ataxia and Alzheimer’s disease. OX1 was tested in human Phase I safety clinical trials involving 90 healthy elderly volunteers and was found to be well tolerated, even at high pharmacological doses.
	Our rights in the intellectual property underlying OX1 are licensed from New York University (“NYU”) and the University of South Alabama Medical Science Foundation (“SAMSF”). Under the agreements with these institutions, we have an exclusive, worldwide, royalty-bearing license, with the right to grant sublicenses relating to OX1. NYU and SAMSF reserve the right to use and practice the licensed patents and know-how for their own non-commercial, educational or research purposes and to distribute certain research materials to third parties for non-commercial uses. Under the agreements, we have the first right to enforce the underlying intellectual property against unauthorized third parties. OX1 sales are subject to royalties due to NYU and SAMSF, and to a royalty obligation arising from the use of test animals licensed to Mindset in drug discovery under a non-exclusive royalty bearing license from the Mayo Foundation for Medical Education and Research (“Mayo”).
	In September 2011, we granted an exclusive license to ViroPharma Inc. (“ViroPharma”) regarding certain of our licensed patents and patent applications related to OX1. In January 2014, ViroPharma merged with Shire Plc. Shire is developing OX1 as a treatment for Friedreich's Ataxia and possibly other diseases for which OX1 may qualify for orphan drug designation.
	In February 2013, ViroPharma filed an investigational new drug application ("IND") to permit initiation of a single ascending dose Phase 1 study to evaluate the safety, tolerability and PK/PD of OX1 (renamed by ViroPharma as "VP 20629") in subjects with FA. The study commenced in the United States in August 2013 and is expected to complete in November 2014. Details of the study, entitled "A Phase 1, Randomized, Double-blind, Placebo-controlled, Multicenter, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Oral VP 20629 in Adult Subjects with Friedreich's Ataxia" may be found at: www.clinicaltrials.gov; identifier NCT01898884.
	Although there can be no assurance, we anticipate that following completion of the Phase 1 study in November 2014, Shire will review the safety of VP 20629 and its possible effect on plasma/urine biomarkers of oxidative stress and thereby decide whether to move to Phase 2. Indication of positive biomarker effects could result in a decision by Shire to seek Orphan Drug designation for VP 20629. We have no ability to control Shire's decision as to whether to seek such designation.
	Abbvie/Shire merger
	On July 18, 2014, it was announced that AbbVie, (Inc.) a research-based biopharmaceutical company, would acquire Shire. As part of the transaction, AbbVie will acquire a series of rare-disease drugs, including Elaprase for Hunter syndrome and Replagal for Fabry disease. The merger has yet to be completed. Although we believe that AbbVie will continue the development of VP 20629, there can be no assurance that AbbVie will do so.
		·	ANTISENILIN® ANTIBODIES - licensed to Global Pharmaceutical Companies:
	The Company has granted non-exclusive licenses related to its ANTISENILIN® patent estate to several global pharmaceutical companies.
	PIPELINE
	Our proprietary pipeline includes:
		·	TauC3 - Alzheimer’s disease:
	In 2012, we licensed a TauC3 antibody from Northwest University, acquiring exclusive global rights to develop and commercialize the antibody. In January 2014, we announced top line data showing proof of concept in a preclinical Alzheimer's model indicating the antibody’s potential to be disease modifying. The study was conducted in collaboration with University of California, Irvine's Dr. Frank LaFerla, Chancellor's Professor and Chair, Neurobiology and Behavior School of Biological Sciences, Director, Institute for Memory Impairments and Neurological Disorders as well as Dr. Kim Green and his team. The data showed that the TauC3 antibody effectively engaged the target and reduced certain phosphorylated pathological forms of Tau indicating that the treatment with the peripherally administered antibody had an effect in the brain and is able to be potentially disease modifying. We have developed a detailed plan and time-line to corroborate these preliminary findings in additional models. This work will be outsourced to specialist contract research organizations and will involve collaboration with a leading AD investigator who has developed models that are particularly well suited to test the TauC3 antibody.
		·	CONJUMAB-A - Age Related Macular Degeneration (AMD):
	We are pursuing the use of antibody drug conjugates (ADCs), in which two different molecules - an antibody and a small molecule - are combined chemically into a single entity. The antibody has a chaperone–like role in clearing the amyloid peptide while the small molecule reduces the neurotoxicity caused by the peptide. This approach, which we refer to as “CONJUMAB” has broad application for the treatment of amyloidosis and other types of proteinopathies. We anticipate that drugs based on CONJUMAB will be comprised of antibodies targeting amyloidogenic polypeptides that are linked chemically to a small molecule that is non-toxic and confers cytoprotective properties, such as an antioxidant or anti-inflammatory molecule.
	CONJUMAB-A aims to combine a monoclonal antibody (IN-N01) targeting amyloid beta in the eye by chemically conjugating the antibody to a derivative of melatonin and thereby combing the amyloid clearing properties of the antibody with a potent antioxidant molecule. We purchased the original monoclonal antibody generated in mice from Immuno- Biological Laboratories (IBL) in Japan and collaborated with London-based Medical Research Council Technology (MRCT) to create a humanized form, IN-N01, which has the same properties as the original antibody.
	We have elected to adopt early application of Accounting Standards Update No. 2014-10, Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements; we no longer present or disclose inception-to-date information and other remaining disclosure requirements of Topic 915.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	12 Months Ended
	Jun. 30, 2014
Accounting Policies [Abstract]	'
Significant Accounting Policies [Text Block]	'
	Note 2. Summary of Significant Accounting Policies
	Principles of Consolidation. The consolidated financial statements include the accounts of our wholly owned subsidiary, Intellect USA.
	Use of Estimates.  The preparation of consolidated financial statements in accordance with accounting principles generally accepted in the United States involves the use of estimates and assumptions that affect the recorded amounts of assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expenses during the reporting period.  Significant estimates include the fair value of derivative instruments, including stock options and warrants to purchase our common stock, recognition of clinical trial costs, certain consulting expenses and deferred taxes.  Actual results may differ substantially from these estimates.
	Stock-Based Compensation. We recognize compensation expense for stock-based compensation in accordance with ASC Topic 718. For employee stock-based awards, we calculate the fair value of the award on the date of grant using the Black-Scholes method for stock options and the quoted price of our common stock for unrestricted shares; the expense is recognized over the service period for awards expected to vest. For non-employee stock-based awards, we calculate the fair value of the award on the date of grant in the same manner as employee awards, however, the awards are revalued at the end of each reporting period and the pro rata compensation expense is adjusted accordingly until such time the nonemployee award is fully vested, at which time the total compensation recognized to date equals the fair value of the stock-based award as calculated on the measurement date, which is the date at which the award recipient’s performance is complete. The estimation of stock-based awards that will ultimately vest requires judgment, and to the extent actual results or updated estimates differ from original estimates, such amounts are recorded as a cumulative adjustment in the period estimates are revised. We consider many factors when estimating expected forfeitures, including types of awards, employee class, and historical experience.
	Research and Development Costs and Clinical Trial Expenses.   Research and development costs, which aggregated $82,620 and $222,300 in the years ended June 30, 2014 and 2013, respectively, include costs directly attributable to the conduct of research and development programs, including the cost of salaries, payroll taxes, employee benefits, materials, supplies, maintenance of research equipment, costs related to research collaboration and licensing agreements, the cost of services provided by outside contractors, including services related to our clinical trials, clinical trial expenses, the full cost of manufacturing drugs for use in research, preclinical development, and clinical trials. All costs associated with research and development are expensed as incurred.
	Revenue Recognition. We recognize revenue in accordance with authoritative accounting guidance, which provides that non-refundable upfront and research and development milestone payments and payments for services are recognized as revenue as the related services are performed over the term of the collaboration.
	Convertible Instruments We evaluate and account for conversion options embedded in convertible instruments in accordance with ASC 815 “Derivatives and Hedging Activities”. Applicable GAAP requires companies to bifurcate conversion options from their host instruments and account for them as free standing derivative financial instruments according to certain criteria. The criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under other GAAP with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument.
	We account for convertible instruments (when we have determined that the embedded conversion options should not be bifurcated from their host instruments) as follows: We record when necessary, discounts to convertible notes for the intrinsic value of conversion options embedded in debt instruments based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note. Debt discounts under these arrangements are amortized over the term of the related debt to their stated date of redemption. We also record when necessary, deemed dividends for the intrinsic value of conversion options embedded in preferred shares based upon the differences between the fair value of the underlying common stock at the commitment date of the transaction and the effective conversion price embedded in the preferred shares.
	Common Stock Purchase Warrants   We classify as equity any contracts that require physical settlement or net-share settlement or provide us a choice of net-cash settlement or settlement in our own shares (physical settlement or net-share settlement) provided that such contracts are indexed to our own stock as defined in ASC 815-40 ("Contracts in Entity's Own Equity"). We classify as assets or liabilities any contracts that require net-cash settlement (including a requirement to net cash settle the contract if an event occurs and if that event is outside our control) or give the counterparty a choice of net-cash settlement or settlement in shares (physical settlement or net-share settlement). We assess classification of our common stock purchase warrants and other free standing derivatives at each reporting date to determine whether a change in classification between assets and liabilities is required.
	Preferred Stock.  We apply the guidance enumerated in ASC 480 “Distinguishing Liabilities from Equity” when determining the classification and measurement of preferred stock. Preferred shares subject to mandatory redemption (if any) are classified as liability instruments and are measured at fair value. We classify conditionally redeemable preferred shares (if any), which includes preferred shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within our control, as temporary equity. At all other times, we classified our preferred shares in stockholders’ equity.
	Derivative Instruments. Our derivative financial instruments consist of embedded derivatives related to the convertible debt, warrants and beneficial conversion features embedded within our convertible debt.  The accounting treatment of derivative financial instruments requires that we record the derivatives and related warrants at their fair values as of the inception date of the debt agreements and at fair value as of each subsequent balance sheet date.  Any change in fair value was recorded as non-operating, non-cash income or expense at each balance sheet date.  If the fair value of the derivatives was higher at the subsequent balance sheet date, we recorded a non-operating, non-cash charge.  If the fair value of the derivatives was lower at the subsequent balance sheet date, we recorded non-operating, non-cash income.
	During the years ended June 30, 2014 and 2013, we recognized other income (expense) of ($745,741) and $2,549,892, respectively, relating to recording the derivative liabilities at fair value.  At June 30, 2014 and 2013, there were approximately $7.2 million and $2.6 million of derivative liabilities outstanding, respectively.
	Our derivative instruments were valued using the Black-Scholes option pricing model, using the following assumptions during the year ended June 30, 2014:
	Estimated dividends		None
	Expected volatility		188%
	Risk-free interest rate		1.73%
	Expected term (years)		1.0 - 5.0 years
	Fair value of financial instruments.   We adopted the provisions of ASC Topic 820, “Fair Value Measurements and Disclosures”, which  defines fair value as used in numerous accounting pronouncements, establishes a framework for measuring fair value and expands disclosure of fair value measurements.
	The estimated fair value of certain financial instruments, including cash and cash equivalents, accounts payable and accrued expenses are carried at historical cost basis, which approximates their fair values because of the short-term nature of these instruments. The carrying amounts of our credit obligations approximate fair value because the effective yields on these obligations, which include contractual interest rates taken together with other features such as concurrent issuances of warrants and/or embedded conversion options, are comparable to rates of returns for instruments of similar credit risk.
	ASC 820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value:
	Level 1 — quoted prices in active markets for identical assets or liabilities
	Level 2 — quoted prices for similar assets and liabilities in active markets or inputs that are observable
	Level 3 — inputs that are unobservable (for example cash flow modeling inputs based on assumptions)
	We measure derivative liabilities at fair value using the Black-Scholes option pricing model with assumptions that include the fair value of the stock underlying the derivative instrument, the exercise or conversion price of the derivative instrument, the risk free interest rate for a term comparable to the term of the derivative instrument and the volatility rate and dividend yield for our common stock. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant. The Company has not paid dividends to date and does not expect to pay dividends in the foreseeable future due to its substantial accumulated deficit. Accordingly, expected dividends yields are currently zero. Expected volatility is based principally on an analysis of historical volatilities of similarly situated companies in the marketplace for a number of periods that is at least equal to the contractual term or estimated life of the applicable financial instrument.
	We also considered the use of the lattice or binomial models with respect to valuing derivative financial instruments that feature anti-dilution price protection; however, the differences in the results are insignificant due to the low probability of triggering price adjustments in such financial instruments.
	We measure the fair value of all of our derivative liabilities based on Level 3 inputs.
	The following table provides a summary of the changes in fair value of all financial liabilities measured at fair value on a recurring basis using significant unobservable inputs during the year ended June 30, 2014.
	Balance - July 1, 2013		$	3,833,457
	Issuances during the year			2,629,990
	Changes in fair value included in earnings			745,741
	Balance - June 30, 2014		$	7,209,188
	Income taxes. We use the asset and liability method of accounting for income taxes in accordance with ASC Topic 740, “Income Taxes.” Under this method, income tax expense is recognized for the amount of: (i) taxes payable or refundable for the current year and (ii) deferred tax consequences of temporary differences resulting from matters that have been recognized in an entity’s financial statements or tax returns. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the results of operations in the period that includes the enactment date. A valuation allowance is provided to reduce the deferred tax assets reported if, based on the weight of the available positive and negative evidence, it is more likely than not some portion or all of the deferred tax assets will not be realized. Tax returns for the years ended June 30, 2011, 2012 and 2013 are subject to audit by the taxing authorities.
	ASC Topic 740.10.30 clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements and prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. ASC Topic 740.10.40 provides guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosure, and transition. We have no material uncertain tax positions for any of the reporting periods presented.
	Net Loss per Share.  Basic net income or basic net loss per common share is computed by dividing net income available to common shareholders by the weighted average number of common shares outstanding during the periods. Diluted earnings per share give effect to dilutive options, warrants, convertible debt and other potential common stock outstanding during the period. Therefore, in the case of a net loss the impact of the potential common stock resulting from warrants, outstanding stock options, convertible debt, and convertible preferred stock are not included in the computation of diluted loss per share, as the effect would be anti-dilutive. In the case of net income the impact of the potential common stock resulting from these instruments that have intrinsic value are included in the diluted earnings per share. The table sets forth the number of potential shares of common stock that have been excluded from diluted net loss per share.
	New Accounting Pronouncements
	In June 2014, the FASB issued ASU No. 2014-10, Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation.
	The amendments in this Update remove the definition of a development stage entity from the Master Glossary of the Accounting Standards Codification, thereby removing the financial reporting distinction between development stage entities and other reporting entities from U.S. GAAP. In addition, the amendments eliminate the requirements for development stage entities to (1) present inception-to-date information in the statements of income, cash flows, and shareholder equity, (2) label the financial statements as those of a development stage entity, (3) disclose a description of the development stage activities in which the entity is engaged, and (4) disclose in the first year in which the entity is no longer a development stage entity that in prior years it had been in the development stage.
	The amendments also clarify that the guidance in Topic 275, Risks and Uncertainties, is applicable to entities that have not commenced planned principal operations.
	Finally, the amendments remove paragraph 810-10-15-16. Paragraph 810-10-15-16 states that a development stage entity does not meet the condition in paragraph 810-10-15-14(a) to be a variable interest entity if (1) the entity can demonstrate that the equity invested in the legal entity is sufficient to permit it to finance the activities that it is currently engaged in and (2) the entity’s governing documents and contractual arrangements allow additional equity investments.
	The amendments also eliminate an exception provided to development stage entities in Topic 810, Consolidation, for determining whether an entity is a variable interest entity on the basis of the amount of investment equity that is at risk. The amendments to eliminate that exception simplify U.S. GAAP by reducing avoidable complexity in existing accounting literature and improve the relevance of information provided to financial statement users by requiring the application of the same consolidation guidance by all reporting entities. The elimination of the exception may change the consolidation analysis, consolidation decision, and disclosure requirements for a reporting entity that has an interest in an entity in the development stage.
	The amendments related to the elimination of inception-to-date information and the other remaining disclosure requirements of Topic 915 should be applied retrospectively except for the clarification to Topic 275, which shall be applied prospectively. For public business entities, those amendments are effective for annual reporting periods beginning after December 15, 2014, and interim periods therein.
	Early application of each of the amendments is permitted for any annual reporting period or interim period for which the entity’s financial statements have not yet been issued (public business entities) or made available for issuance (other entities). Upon adoption, entities will no longer present or disclose any information required by Topic 915.
	In August 2014, the FASB issued the FASB Accounting Standards Update No. 2014-15 “Presentation of Financial Statements—Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern (“ASU 2014-15”).
	In connection with preparing financial statements for each annual and interim reporting period, an entity’s management should evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the date that the financial statements are issued (or within one year after the date that the financial statements are available to be issued when applicable). Management’s evaluation should be based on relevant conditions and events that are known and reasonably knowable at the date that the financial statements are issued (or at the date that the financial statements are available to be issued when applicable). Substantial doubt about an entity’s ability to continue as a going concern exists when relevant conditions and events, considered in the aggregate, indicate that it is probable that the entity will be unable to meet its obligations as they become due within one year after the date that the financial statements are issued (or available to be issued). The term probable is used consistently with its use in Topic 450, Contingencies.
	When management identifies conditions or events that raise substantial doubt about an entity’s ability to continue as a going concern, management should consider whether its plans that are intended to mitigate those relevant conditions or events will alleviate the substantial doubt. The mitigating effect of management’s plans should be considered only to the extent that (1) it is probable that the plans will be effectively implemented and, if so, (2) it is probable that the plans will mitigate the conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern.
	If conditions or events raise substantial doubt about an entity’s ability to continue as a going concern, but the substantial doubt is alleviated as a result of consideration of management’s plans, the entity should disclose information that enables users of the financial statements to understand all of the following (or refer to similar information disclosed elsewhere in the footnotes):
		a.	Principal conditions or events that raised substantial doubt about the entity’s ability to continue as a going concern (before consideration of management’s plans)
		b.	Management’s evaluation of the significance of those conditions or events in relation to the entity’s ability to meet its obligations
		c.	Management’s plans that alleviated substantial doubt about the entity’s ability to continue as a going concern.
	If conditions or events raise substantial doubt about an entity’s ability to continue as a going concern, and substantial doubt is not alleviated after consideration of management’s plans, an entity should include a statement in the footnotes indicating that there is substantial doubt about the entity’s ability to continue as a going concern within one year after the date that the financial statements are issued (or available to be issued). Additionally, the entity should disclose information that enables users of the financial statements to understand all of the following:
		a.	Principal conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern
		b.	Management’s evaluation of the significance of those conditions or events in relation to the entity’s ability to meet its obligations
		c.	Management’s plans that are intended to mitigate the conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern.
	The amendments are effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter.
	We have elected to adopt early application of Accounting Standards Update No. 2014-10, Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements; we no longer present or disclose inception-to-date information and other remaining disclosure requirements of Topic 915.
	Management does not believe that any other recently issued, but not yet effective accounting pronouncements, when adopted, will have a material effect on the accompanying financial statements.

Material_Agreements

Material Agreements	12 Months Ended
	Jun. 30, 2014
Material Agreements [Abstract]	'
Material Agreements Disclosure [Text Block]	'
	Note 3.  Material Agreements
	Mindset Asset Transfer Agreement. Several of Intellect’s assets were acquired in 2005 from Mindset Biopharmaceuticals, Inc., which we refer to as “Mindset”.
	Research and License Agreements with South Alabama Medical Science Foundation (“SAMS”) and New York University (“NYU”). Effective August 1998, and as amended, Mindset entered into Reserved and License Agreements (“RLAs”) with SAMS and NYU. In June 2005, SAMS and NYU consented to Mindset's assignment of the RLAs to us. Under the RLAs, we have an exclusive, worldwide, royalty-bearing license, with the right to grant sublicenses, under certain patents and know-how relating to the use of indole-3-propionic acid among other things, to prevent Alzheimer’s disease. We are obligated to make future payments to SAMS and NYU totaling approximately $3,000,000 upon achievement of certain milestones based on phases of clinical development and approval of the FDA (or foreign equivalent) and also to pay SAMS and NYU royalties on net sales (as defined) attributable to each product utilizing the licensed technology. Additionally, we are obligated to pay a percentage of all sublicense fees received by the Company. In September 2011, we granted a sublicense of the RLAs to ViroPharma. Pursuant to the terms of the RLAs as amended, we have paid each of SAMS and NYU $650,000 of the up-font licensing fee and are required to pay a portion of future payments we may receive from ViroPharma. (See ViroPharma License Agreement below.)
	Beta-Amyloid Specific, Humanized Monoclonal Antibody Purchase and Sale Agreement. In December 2006, we entered into Beta-Amyloid Specific, Humanized Monoclonal Antibody Purchase and Sale Agreement (the "IBL Agreement") with Immuno-Biological Laboratories Co., Ltd. ("IBL"). Pursuant to the IBL Agreement, we acquired two beta amyloid specific monoclonal antibodies ready for humanization, and the IBL patents or applications relating to them. In consideration, we agreed to pay IBL a total of $2,125,000 upon the achievement of certain milestones plus a specified royalty based on sales of any pharmaceutical product derived from the antibodies. Also, we granted to IBL a worldwide, exclusive, paid-up license under certain of our granted patents and pending applications in Japan. The IBL Agreement expires upon the last to expire of the relevant Intellect patents, unless earlier terminated as the result of a material breach by or certain bankruptcy related events of either party to the agreement.
	Élan Pharma International Limited and Wyeth License Agreement. In May 2008, we entered into a License Agreement with AHP Manufacturing BV, acting through its Wyeth Medica Ireland Branch, (“Wyeth”) and Elan Pharma International Limited (“Elan”) to provide Wyeth and Elan (collectively, the “Licensees”) with certain license rights under certain of our patents and patent applications (the “Licensed Patents”) relating to certain antibodies that may serve as potential therapeutic products for the treatment for AD (the “Licensed Products”).
	We granted the Licensees a non-exclusive license under the Licensed Patents to research, develop, manufacture and commercialize Licensed Products. We received an upfront payment of $1 million in May 2008 and an additional $1 million in August 2008. We are eligible to receive certain milestones and royalties based on the sale of Licensed Products.
	The Licensees have an option to receive ownership of the Licensed Patents if at any time during the term we abandon all activities related to research, development and commercialization of our products that are covered by the Licensed Patents and no other licenses granted by us under the Licensed Patents remain in force. Failure to incur $50,000 in patent or program research related expenses during any six month period is considered to be abandonment. As described more fully below, we granted a license under the Licensed Patents to another pharmaceutical company in December 2008 and reclassified the balance of the deferred credit as revenue because the grant of the second license removed the requirement contained in the abandonment clause in this Agreement. We initially recorded the up-front payment of $1 million that we received from the Licensees in May 2008 as a deferred credit, representing our obligation to fund such future patent or program research related expenses, and we recorded periodic amortization expense related to the deferred credit based on the remaining life of the License. We accounted for the payment received in August 2008 as revenue in the period of receipt.
	ANTISENILIN Option and License Agreement. In October 2008, we entered into an Option Agreement with a global pharmaceutical company (“Option Holder”) regarding an option to obtain a license under certain of our patents and patent applications (the “Subject Patents”) related to antibodies and methods of treatment for AD and to make, have made, use, sell, offer to sell and import certain Licensed Products, as defined in this agreement.
	We granted the Option Holder an irrevocable option to acquire a non-exclusive, royalty bearing license under the Subject Patents. In consideration, the Option Holder paid us a non-refundable fee of $500,000 and agreed to pay us $2,000,000 upon exercise of the option (the “Exercise Fee”). We are entitled to receive an additional $2,000,000 upon the grant in the United States of a Licensed Patent with at least one Valid Claim that covers a Licensed Product in the Territory in the Field (as such terms are defined in this agreement). An additional milestone payment shall be made to us should the Option Holder achieve certain thresholds for aggregate annual net sales. The agreement also provides that we will be eligible to receive certain royalty payments from the Option Holder in connection with net sales.
	In December 2008, the Option Holder exercised the option and paid us $1,550,000, which is the Exercise Fee, as adjusted.
	GSK Option and License Agreement. In April 2009, we entered into an Option Agreement with Glaxo Group Limited (“GSK”) regarding an option to purchase a license under certain of our patents and patent applications (the “GSK Patents”) related to antibodies and methods of treatment for AD. We granted GSK an irrevocable option to acquire a non-exclusive, royalty bearing license under the GSK Patents with the right to grant sublicenses, to develop, have developed, make, have made, use, offer to sell, sell, import and have imported Licensed Products.
	Upon exercise of the option, GSK will pay us $2,000,000 and, upon the later to occur of the exercise of the option by GSK and grant to us in the United States of a Licensed Patent with at least one Valid Claim that covers a Licensed Product incorporating a GSK Compound, GSK will pay us an additional $2,000,000. An additional milestone payment will be made to us should GSK achieve certain thresholds of annual net sales. This agreement also provides that we will be eligible to receive certain royalty payments from GSK in connection with net sales.
	ViroPharma License Agreement. On and effective as of September 29, 2011, we entered into an Exclusive License Agreement (the “License Agreement”) with ViroPharma, pursuant to which, among other things we granted an exclusive license to ViroPharma regarding certain of our licensed patents and patent applications related to OX1.
	Under the terms of the License Agreement, we have agreed to transfer to ViroPharma all of our intellectual property rights, data and know-how related to our OX1 research and development program in exchange for payment by ViroPharma of a $6.5 million up-front licensing fee and additional regulatory milestone payments based upon defined events in the United States and the European Union. The aggregate maximum of these milestone payments assuming successful advancement of the product to market could amount to $120 million. In addition, ViroPharma will pay us a tiered royalty based on annual net sales. NYU School of Medicine and South Alabama Medical Science Foundation, which own certain patents in relation to OX1, are entitled to a portion of the royalties and revenues received by us from any sale or license of OX1 pursuant to the RLAs described above.
	The term of the License Agreement will continue in effect on a licensed product-by-licensed product and country-by-country basis until the expiration of the last royalty obligation with respect to a licensed product in such country. Once the royalty obligation has terminated in a particular country, the license will become non-exclusive and fully paid-up with respect to licensed products in that country.
	Either party may terminate the License Agreement upon an uncured material breach of the other party. In addition, if ViroPharma determines that it is not feasible or desirable to develop or commercialize licensed products, it may terminate the License Agreement in whole or on a product-by-product basis at any time upon ninety (90) days prior written notice to the Company. In the event of a termination of the License Agreement, other than ViroPharma’s termination of the License Agreement for the Company’s uncured material breach, we will have an exclusive, perpetual, irrevocable, worldwide, royalty-bearing license to exploit the licensed products.
	In January 2014, ViroPharma merged with Shire Plc. We believe Shire is developing OX1 as a treatment for Friedreich's Ataxia and possibly other diseases for which OX1 may qualify for orphan drug designation.
	License Agreement with Northwestern University (“NWU”). Effective May 2012, we entered into a License Agreement (“License”) with NWU pursuant to which we obtained an exclusive, worldwide, royalty-bearing license, with the right to grant sublicenses, under certain patents and know-how relating to the use of monoclonal antibody Tau C3 and TOC-1 for the prophylaxis, mitigation, diagnosis and/or treatment of AD and other tauopathies. We are obligated to make future payments to NWU totaling approximately $700,000 upon achievement of certain milestones based on phases of clinical development and also to pay NWU royalties on net sales (as defined) attributable to each product utilizing the licensed technology.

Convertible_Notes_Payable

Convertible Notes Payable	12 Months Ended
	Jun. 30, 2014
Debt Disclosure [Abstract]	'
Debt Disclosure [Text Block]	'
	Note 4.   Convertible Notes Payable
	The following table presents the components of Convertible Notes Payable at June 30, 2014 and June 30, 2013:
					June 30, 2014		June 30, 2013
	(a)		Convertible Notes issued during fiscal year ended June 30, 2010		$	80,000	$	80,000
	(b)		Convertible Notes issued during fiscal year ended June 30, 2011		$	1,100,000	$	1,100,000
	(c)		Convertible Notes issued during fiscal year ended June 30, 2012		$	451,500	$	451,500
	(d)		Convertible Notes issued during fiscal year ended June 30, 2013		$	1,136,000	$	1,136,000
	(e)		Convertible Notes issued during fiscal year ended June 30, 2014		$	527,500
			Balance at End of Period		$	3,295,000	$	2,767,500
			Less debt discount:		$	1,103,345	$	2,180,803
			Convertible Notes Payable, Net		$	2,191,655	$	586,697
			Classified as follows on the accompanying consolidated balance sheets:
			Current portion of Convertible Notes Payable		$	1,464,452	$	645,040
			Long term portion of Convertible Notes Payable		$	727,203	$	586,697
					$	2,191,655	$	1,231,737
		(a)	During fiscal year ended June 30, 2010, we issued Convertible Promissory Notes of $730,000, which carry interest at 14% annually, mature three years from the issue date and are convertible into the Company's common shares at a conversion price of $0.01 per share. As of June 30, 2014, Notes of $80,000 were in default. These Notes were repaid in July 2014.
		(b)	During fiscal year ended June 30, 2011, we issued Convertible Promissory Notes of $1,100,000, which carry interest at 14% annually, mature three years from the issue date and are convertible into the Company's common shares at a conversion price of $0.01 per share. As of June 30, 2014, these Notes were in default. Notes of $220,000 were repaid in July 2014.
		(c)	During fiscal year ended June 30, 2012, we issued Convertible Promissory Notes of $451,500, which carry interest at 14% annually, mature three years from the issue date and are convertible into the Company's common shares at a conversion price of $0.01 per share.
		(d)	During fiscal year ended June 30, 2013, we issued Convertible Promissory Notes of $1,136,000, which carry interest at 14% annually, mature three years from the issue date and are convertible into the Company's common shares at a conversion price of $0.01 per share.
		(e)	During fiscal year ended June 30, 2014, we issued Convertible Promissory Notes with an aggregate principal amount of $527,500. These Notes carry interest at 14% annually (payable in arrears), mature three years from the issue date and are convertible into the Company's common shares at a conversion price of $0.01 per share.
	Convertible Notes Payable are payable as follows:
	Fiscal year ended June 30, 2015		$	1,631,500
	Fiscal year ended June 30, 2016		$	1,136,000
	Fiscal year ended June 30, 2017		$	527,500
	Total		$	3,295,000

Convertible_Preferred_Stock

Convertible Preferred Stock	12 Months Ended
	Jun. 30, 2014
Equity [Abstract]	'
Preferred Stock [Text Block]	'
	Note 5. Convertible Preferred Stock
	Series B Convertible Preferred Stock
	The Series B Convertible Preferred Stock carries a cumulative dividend of 6% per annum and a stated value of $17.50 per share. Each share is convertible into 11.67 common shares based on the current conversion price of $1.50.
	Series C Convertible Preferred Stock
	The Series C Convertible Preferred Stock carries a cumulative dividend of 14% per annum and a stated value of $1,000 per share. Each share is convertible into 100,000 common shares based on the current conversion price of $0.01. During the years ended June 30, 2014 and 2013, 543 and 570 shares, respectively were converted into 54,214,500 and 37,000,000 common shares, respectively.
	Series D Convertible Preferred Shares
	The Series D Convertible Preferred Stock carries a cumulative dividend of 8% per annum and a stated value of $1,000 per share. Each share is convertible into 100,000 common shares based on the current conversion price of $0.01. During the years ended June 30, 2014 and 2013, 841 and 250 shares, respectively were converted into 84,098,622 and 25,000,000 common shares, respectively.
	Series E Convertible Preferred Shares
	The Series E Convertible Preferred Stock carries a cumulative dividend of 8% per annum and a stated value of $1,000 per share. Each share is convertible into 100,000 common shares based on the current conversion price of $0.01.

Outstanding_Warrants

Outstanding Warrants	12 Months Ended
	Jun. 30, 2014
Derivative Instruments and Hedging Activities Disclosure [Abstract]	'
Derivative Instruments and Hedging Activities Disclosure [Text Block]	'
	Note 6. Outstanding Warrants
	The following table presents the number of Warrants outstanding at year end June 30, 2014 and June 30, 2013. All Warrants have a 5 year term, an exercise price of $0.01 per common share and are exercisable at June 30, 2014. (See Note 12, Subsequent Events)
	Warrants outstanding at June 30, 2012	182,020,022
	Issued	412,750,000
	Exchanged for Series D Preferred Stock	-182,020,022
	Exercised	-46,000,000
	Expired	-
	Balance at the end of period	366,750,000
	Issued	318,750,000
	Exercised	-
	Expired	-
	Warrants outstanding at June 30, 2014	685,500,000

Income_Taxes

Income Taxes	12 Months Ended
	Jun. 30, 2014
Income Tax Disclosure [Abstract]	'
Income Tax Disclosure [Text Block]	'
	Note 7. Income Taxes
	The reconciliation of income tax benefit at the U.S. statutory rate of 34% for the years ended June 30, 2014 and 2013 to the Company’s effective tax rate is as follows:
		Years Ended
		June 30, 2014		June 30, 2013
	U.S. federal statutory rate	-34	%	-34	%
	State income tax, net of federal benefit	-6	%	-6	%
	Change in valuation allowance	40	%	40	%
	Income Tax provision (benefit)	0	%	0	%
	The tax effects of temporary differences that give rise to the Company’s net deferred tax asset as of June 30, 2014 and 2013 are as follows:
		June 30, 2014		June 30, 2013
	Deferred Tax Assets
	Net operating losses	$	8,500,000	$	7,120,000
	Derivative liability		2,883,700		2,146,800
			11,383,700		9,266,800
	Less: Valuation allowance		-8,500,000		-7,120,000
	Net Deferred Tax Assets	$	2,883,700	$	2,146,800
	Deferred Tax Liabilities
	Derivative liability		-2,883,700		-2,146,800
	Total Deferred Tax Liabilities		-2,883,700		-2,146,800
	Net Deferred taxes		-		-
	As of June 30, 2014, the Company had approximately $21,000,000 of Federal and state net operating loss carryovers (“NOLs”) which begin to expire in 2025. Utilization of the NOLs may be subject to limitation under Internal Revenue Code Section 382 should there be a greater than 50% ownership change as determined under regulations.
	In assessing the realization of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment. Based on the assessment, management has established a full valuation allowance against all of the deferred tax asset because it is more likely than not that all of the deferred tax asset will not be realized.
	The Company files U.S. federal and state of New York tax returns that are subject to audit by tax authorities beginning with the year ended June 30, 2010. The Company is not currently under audit for any tax returns

Capital_Deficiency

Capital Deficiency	12 Months Ended
	Jun. 30, 2014
Equity Method Investments and Joint Ventures [Abstract]	'
Equity Method Investments Disclosure [Text Block]	'
	Note 8. Capital Deficiency
	Common stock
	During the fiscal year ended June 30, 2013, we issued 62 million shares of our common stock to holders of Convertible Preferred Stock upon their exercise of the conversion feature contained in those securities.
	During the fiscal year ended June 30, 2013, we issued 17,250,000 shares of our common stock in consideration for services rendered to the Company.
	In March 2013, we issued 29,525,879 shares of our common stock to holders of 46,000,000 warrants upon their cashless exercise of the conversion feature contained in those securities.
	During the fiscal year ended June 30, 2014, we issued 138,313,122 shares of our common stock to holders of Convertible Preferred Stock upon their exercise of the conversion feature contained in those securities.
	During the fiscal year ended June 30, 2014, we issued 34,500,000 shares of our common stock in consideration for services rendered to the Company.
	In October 2013, we issued 13,183,055 shares of our common stock to holders of July 2011 Notes with an aggregate face amount of $100,000 in exchange for cancellation of all principal and accrued interest due with respect to such Notes.
	During the fiscal year ended June 30, 2014, we issued 4,500,000 shares of our common stock to charitable organizations as charitable donations.

Commitments_and_Contingencies

Commitments and Contingencies	12 Months Ended
	Jun. 30, 2014
Commitments and Contingencies Disclosure [Abstract]	'
Commitments and Contingencies Disclosure [Text Block]	'
	Note 9. Commitments and Contingencies.
	On December 24, 2012, we filed a complaint against certain defendants (“Defendants”) seeking $2 million in damages.
	In response to our complaint, Defendants, in February 2013, filed a Motion to Dismiss the Complaint. Upon hearing oral arguments on January 8, 2014, the Court denied Defendants’ motion to dismiss the breach of contract claim. On February 7, 2014, Defendants filed an Answer to our Complaint, denying our complaints and counter-suing for an alleged breach of confidentiality. We filed a reply to Defendants’ counterclaim on February 27, 2014. There have been various status conferences since February 2014 related to pre-trial discovery, which is continuing.
	In the ordinary course of business, we enter into agreements with third parties that include indemnification provisions which, in our judgment, are normal and customary for companies in our industry sector. These agreements are typically with business partners, clinical sites, and suppliers. Pursuant to these agreements, we generally agree to indemnify, hold harmless, and reimburse indemnified parties for losses suffered or incurred by the indemnified parties with respect to our product candidates, use of such product candidates, or other actions taken or omitted by us. The maximum potential amount of future payments we could be required to make under these indemnification provisions is unlimited. We have not incurred material costs to defend lawsuits or settle claims related to these indemnification provisions. As a result, the estimated fair value of liabilities relating to these provisions is minimal. Accordingly, we have no liabilities recorded for these provisions as of June 30, 2014 and 2013.
	In the normal course of business, we may be confronted with issues or events that may result in a contingent liability. These generally relate to lawsuits, claims, environmental actions or the action of various regulatory agencies. If necessary, management consults with counsel and other appropriate experts to assess any matters that arise. If, in management’s opinion, we have incurred a probable loss as set forth by accounting principles generally accepted in the United States, an estimate is made of the loss, and the appropriate accounting entries are reflected in our financial statements. We do not anticipate that liabilities arising out of currently pending or threatened lawsuits and claims will have a material adverse effect on our financial position, results of operations or cash flows.

StockBased_Compensation_Plans

Stock-Based Compensation Plans	12 Months Ended
	Jun. 30, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	'
	Note 10. Stock-Based Compensation Plans-
	In December 2006, our stockholders approved the adoption of the "2006 Employee, Director and Consultant Stock Plan" (the "2006 Stock Plan"), under which 240,000 shares of our common stock are available for issuance under the Plan.  The 2006 Stock Plan provides for the grant of either ISOs or non-qualified stock options, which do not qualify as ISOs.
	On March 30, 2009, we granted 500 stock options to a consultant engaged by the Company to assist in research and development activities related to OX1. The grant was effective as of that date with a strike price of $17.50.  The stock options vest over a twelve month period and expired on March 30, 2014.
	On August 31, 2010, we granted 2,000 stock options to a consultant engaged by the Company to assist in research and development activities. The grant was effective as of that date with a strike price of $0.83. The stock options vest over a twelve month period and are exercisable through August 31, 2015.
	On June 13, 2011, we granted 10,000 stock options to a consultant engaged by the Company to assist in research and development activities. The grant was effective as of that date with a strike price of $0.10. The stock options vest over a twelve month period and are exercisable through June 13, 2016.
	The exercise price of all the above stock options was the closing price of the stock on the day of the grant.
	As of June 30, 2014 and 2013, there are  228,000 and 26,757 stock options available for grant under the 2006 Stock Plan, respectively.
	A summary of the transaction in the 2006 Stock Plan is as follows:
			Weighted		Instrinisic		Weighted
			Average		value		Average
			Exercise Price				Remaining
							Contractual
							Life
	Options outstanding at June 30, 2012	213,243	$	34.87	$	-		3.35
	Granted	-	$	-				-
	Cancelled/Forfeited	-	$	-		-
	Expired	-	$	-
	Balance at the end of period	213,243	$	34.87		-		3.35
	Options excercisable at June 30, 2013	213,243	$	34.87		-		3.35
	Expired	201,243	$	34.87
	Balance at June 30, 2014	12,000	$	0.22				2
	Options vested or expected to vest	12,000	$	0.22		-		2
	Total compensation expense recorded during the year ended June 30, 2014 and 2013 for share-based payment awards was $0.

Per_Share_Data

Per Share Data	12 Months Ended
	Jun. 30, 2014
Earnings Per Share [Abstract]	'
Earnings Per Share [Text Block]	'
	Note 11. Per Share Data
	For the years ended June 30, 2014 and 2013 all common stock equivalents have been determined to be anti-dilutive and have not been considered in the calculation of diluted weighted average shares outstanding on the statement of operations.

Subsequent_Events

Subsequent Events	12 Months Ended
	Jun. 30, 2014
Subsequent Events [Abstract]	'
Subsequent Events [Text Block]	'
	Note 12. Subsequent Events
	In accordance with authoritative guidance, we have evaluated any events or transactions occurring after June 30, 2014, the balance sheet date, through the date of filing of this report and note that there have been no such events or transactions that would require recognition or disclosure in the consolidated financial statements as of and for the year ended June 30, 2014, except as disclosed below.
	In July 2014, we issued 65 million shares of our common stock to holders of Series C Convertible Preferred Stock upon their exercise of the conversion feature contained in those securities.
	In August 2014, we issued 84 million shares of our common stock to holders of Series C Convertible Preferred Stock upon their exercise of the conversion feature contained in those securities.
	In September 2014, we issued 65 million shares of our common stock to holders of Series C Convertible Preferred Stock upon their exercise of the conversion feature contained in those securities
	July 2014 Financing
	On July 25, 2014, (the “Closing Date”) we entered into a stock purchase agreement with certain accredited investors (the “Investors”) whereby we issued to the Investors an aggregate 1,200 shares of Series F Convertible Preferred Stock and warrants (the “Warrants”) to purchase an aggregate of 2.4 billion shares of common stock, par value $0.001 per share (the “Common Stock”) of the Company (the “Financing”).
	The Series F Preferred Stock has a right to liquidation preference and is convertible at any time into shares of the Common Stock of the Company at a conversion price of $0.001, subject to adjustment. Each share of Series F Preferred Stock has a stated value of $1,000 (the “Stated Value”) and accrues a dividend of 8% of the Stated Value per annum, which is payable annually on June 30th in cash or, at the holder’s option, in Common Stock, or a combination thereof. The Series F Preferred Stock has no voting rights and holders thereof shall vote together with holders of Common Stock on an as converted basis. The Warrants are exercisable for a period of five (5) years from the date of issuance and are exercisable into shares of Common Stock of the Company at an exercise price of $0.001 per share, subject to adjustment.
	On July 25, 2014, the Company entered into a registration rights agreement (the “Registration Rights Agreement”) with the Investors under which the Company agreed to prepare and file with the SEC and maintain the effectiveness of a “resale” registration statement (the “Registration Statement”) providing for the resale of (a) all of the shares of Common Stock issuable upon conversion in full of the Series F Preferred Stock, (b) all shares of Common Stock issuable as dividends on the Series F Preferred Stock, (c) all of the shares of Common Stock issuable upon exercise of the Warrants and (d) any securities issued or then issuable upon any stock split, dividend or other distribution, recapitalization or similar event with respect to the foregoing (collectively, the “Registrable Securities”).
	Under the terms of the Registration Rights Agreement, the Company is required to file a Registration Statement with the SEC within 115 days after the Closing Date and declared effective by the SEC not later than 180 days from the Closing Date. The Registration Rights Agreement also grants holders of Registrable Securities customary piggy back rights during any time there is not an effective registration statement providing for the resale of the Registrable Securities.
	In connection with the Financing, the Company filed a (i) Certificate of Amendment to the Certificate of Designations, Preferences and Rights of Series B Convertible Preferred Stock, (ii) Certificate of Amendment to the Certificate of Designations, Preferences and Rights of Series C Convertible Preferred Stock, (iii) Certificate of Amendment to the Certificate of Designations, Preferences and Rights of Series D Convertible Preferred Stock and (iv) Certificate of Amendment to the Certificate of Designations, Preferences and Rights of Series E Convertible Preferred Stock.
	In connection with the Financing, the Company and a majority of each Series B, Series C, Series D and Series E Preferred Stock, by written consent, agreed to the amendment of each respective series as follows, effective as of the Closing Date:
		·	Series B Preferred Stock · Eliminate the ratchet provision for subsequent issuances of securities.
		·	Series C Preferred Stock · The conversion price per share of Common Stock shall be $0.005; and eliminate the ratchet provision for subsequent issuances of securities.
		·	Series D Preferred Stock · The conversion price per share of Common Stock shall be $0.005; and eliminate the ratchet provision for subsequent issuances of securities.
		·	Series E Preferred Stock · Eliminate the ratchet provision for subsequent issuances of securities.
		·	Series B, Series C, Series D and Series E Preferred Stock · Waive the covenant of the Company to refrain from issuing any shares of capital stock senior to or on parity with each series of preferred stock, and to reserve and keep available unissued shares of Common Stock for the purpose of effecting the conversion of the shares of each series of preferred stock for a period of six (6) months from the Closing Date.
	In connection with the Financing, pursuant to consents and waivers obtained from holders of the Company’s outstanding convertible promissory notes (the “Promissory Notes”) their respective Promissory Notes were amended as follows, effective upon the issuance of one or more shares of Series F Preferred Stock: (i) eliminate the ratchet provision for subsequent issuances of securities going forward, (ii) waive the covenant of the Company to reserve and keep available unissued shares of Common Stock for the purpose of effecting the conversion of the Promissory Notes and (iii) provide that the conversion price shall be $0.005, but for two of the holders holding an aggregate of $845,000 principal amount of Promissory Notes, the conversion price shall be equal to $0.00032 per share of Common Stock and $0.00055 per share of Common Stock.
	In connection with the Financing, the holders of the Company’s outstanding warrants, exclusive of the Warrants issued as part of the Financing, (the “Outstanding Warrants”) agreed as follows, effective upon the issuance of one or more Series F Preferred Stock: (i) eliminate the ratchet provision for subsequent issuances of securities going forward, (ii) waive the covenant of the Company to reserve and keep available unissued shares of Common Stock for the purpose of effecting the conversion of the Outstanding Warrants for a period of six (6) months from the Closing Date and (iii) provide that the exercise price of the Outstanding Warrants be the effective price per share, upon cashless exercise, shall be 50% of the fair market value of the Common Stock on the date of exercise.
	In connection with the Financing, the Company satisfied by cash payment $300,000 of principal and accrued interest on outstanding promissory notes of a certain investor and purchased from such investor convertible preferred stock, and dividends accrued thereon, having an aggregate stated value of $16,750,000 for the total consideration of $100.
	On August 14, 2014, we filed a Certificate of Amendment (the “Amendment”) with the Secretary of State of the State of Delaware providing for a reverse stock split whereby for every two hundred and fifty (250) shares of common stock issued and outstanding, two hundred and fifty (250) shares of common stock shall be combined and converted into one (1) share of common stock. We filed the Amendment on the basis of approval of the Board of Directors of the Company following approval by a majority of the holders of all classes of convertible preferred stock, voting on an “as converted basis”. Subsequently, the Board has decided to put the matter to a vote of all common shareholders.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Jun. 30, 2014
Accounting Policies [Abstract]	'
Consolidation, Policy [Policy Text Block]	'
	Principles of Consolidation. The consolidated financial statements include the accounts of our wholly owned subsidiary, Intellect USA.
Use of Estimates, Policy [Policy Text Block]	'
	Use of Estimates.  The preparation of consolidated financial statements in accordance with accounting principles generally accepted in the United States involves the use of estimates and assumptions that affect the recorded amounts of assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expenses during the reporting period.  Significant estimates include the fair value of derivative instruments, including stock options and warrants to purchase our common stock, recognition of clinical trial costs, certain consulting expenses and deferred taxes.  Actual results may differ substantially from these estimates.
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	'
	Stock-Based Compensation. We recognize compensation expense for stock-based compensation in accordance with ASC Topic 718. For employee stock-based awards, we calculate the fair value of the award on the date of grant using the Black-Scholes method for stock options and the quoted price of our common stock for unrestricted shares; the expense is recognized over the service period for awards expected to vest. For non-employee stock-based awards, we calculate the fair value of the award on the date of grant in the same manner as employee awards, however, the awards are revalued at the end of each reporting period and the pro rata compensation expense is adjusted accordingly until such time the nonemployee award is fully vested, at which time the total compensation recognized to date equals the fair value of the stock-based award as calculated on the measurement date, which is the date at which the award recipient’s performance is complete. The estimation of stock-based awards that will ultimately vest requires judgment, and to the extent actual results or updated estimates differ from original estimates, such amounts are recorded as a cumulative adjustment in the period estimates are revised. We consider many factors when estimating expected forfeitures, including types of awards, employee class, and historical experience.
Research and Development Expense, Policy [Policy Text Block]	'
	Research and Development Costs and Clinical Trial Expenses.   Research and development costs, which aggregated $82,620 and $222,300 in the years ended June 30, 2014 and 2013, respectively, include costs directly attributable to the conduct of research and development programs, including the cost of salaries, payroll taxes, employee benefits, materials, supplies, maintenance of research equipment, costs related to research collaboration and licensing agreements, the cost of services provided by outside contractors, including services related to our clinical trials, clinical trial expenses, the full cost of manufacturing drugs for use in research, preclinical development, and clinical trials. All costs associated with research and development are expensed as incurred.
Revenue Recognition, Policy [Policy Text Block]	'
	Revenue Recognition. We recognize revenue in accordance with authoritative accounting guidance, which provides that non-refundable upfront and research and development milestone payments and payments for services are recognized as revenue as the related services are performed over the term of the collaboration.
Debt, Policy [Policy Text Block]	'
	Convertible Instruments We evaluate and account for conversion options embedded in convertible instruments in accordance with ASC 815 “Derivatives and Hedging Activities”. Applicable GAAP requires companies to bifurcate conversion options from their host instruments and account for them as free standing derivative financial instruments according to certain criteria. The criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under other GAAP with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument.
	We account for convertible instruments (when we have determined that the embedded conversion options should not be bifurcated from their host instruments) as follows: We record when necessary, discounts to convertible notes for the intrinsic value of conversion options embedded in debt instruments based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note. Debt discounts under these arrangements are amortized over the term of the related debt to their stated date of redemption. We also record when necessary, deemed dividends for the intrinsic value of conversion options embedded in preferred shares based upon the differences between the fair value of the underlying common stock at the commitment date of the transaction and the effective conversion price embedded in the preferred shares.
Common Stock Purchase Warrants [Policy Text Block]	'
	Common Stock Purchase Warrants   We classify as equity any contracts that require physical settlement or net-share settlement or provide us a choice of net-cash settlement or settlement in our own shares (physical settlement or net-share settlement) provided that such contracts are indexed to our own stock as defined in ASC 815-40 ("Contracts in Entity's Own Equity"). We classify as assets or liabilities any contracts that require net-cash settlement (including a requirement to net cash settle the contract if an event occurs and if that event is outside our control) or give the counterparty a choice of net-cash settlement or settlement in shares (physical settlement or net-share settlement). We assess classification of our common stock purchase warrants and other free standing derivatives at each reporting date to determine whether a change in classification between assets and liabilities is required.
Stockholders' Equity Note, Redeemable Preferred Stock, Issue, Policy [Policy Text Block]	'
	Preferred Stock.  We apply the guidance enumerated in ASC 480 “Distinguishing Liabilities from Equity” when determining the classification and measurement of preferred stock. Preferred shares subject to mandatory redemption (if any) are classified as liability instruments and are measured at fair value. We classify conditionally redeemable preferred shares (if any), which includes preferred shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within our control, as temporary equity. At all other times, we classified our preferred shares in stockholders’ equity.
Derivatives, Policy [Policy Text Block]	'
	Derivative Instruments. Our derivative financial instruments consist of embedded derivatives related to the convertible debt, warrants and beneficial conversion features embedded within our convertible debt.  The accounting treatment of derivative financial instruments requires that we record the derivatives and related warrants at their fair values as of the inception date of the debt agreements and at fair value as of each subsequent balance sheet date.  Any change in fair value was recorded as non-operating, non-cash income or expense at each balance sheet date.  If the fair value of the derivatives was higher at the subsequent balance sheet date, we recorded a non-operating, non-cash charge.  If the fair value of the derivatives was lower at the subsequent balance sheet date, we recorded non-operating, non-cash income.
	During the years ended June 30, 2014 and 2013, we recognized other income (expense) of ($745,741) and $2,549,892, respectively, relating to recording the derivative liabilities at fair value.  At June 30, 2014 and 2013, there were approximately $7.2 million and $2.6 million of derivative liabilities outstanding, respectively.
	Our derivative instruments were valued using the Black-Scholes option pricing model, using the following assumptions during the year ended June 30, 2014:
	Estimated dividends		None
	Expected volatility		188%
	Risk-free interest rate		1.73%
	Expected term (years)		1.0 - 5.0 years
Fair Value of Financial Instruments, Policy [Policy Text Block]	'
	Fair value of financial instruments.   We adopted the provisions of ASC Topic 820, “Fair Value Measurements and Disclosures”, which  defines fair value as used in numerous accounting pronouncements, establishes a framework for measuring fair value and expands disclosure of fair value measurements.
	The estimated fair value of certain financial instruments, including cash and cash equivalents, accounts payable and accrued expenses are carried at historical cost basis, which approximates their fair values because of the short-term nature of these instruments. The carrying amounts of our credit obligations approximate fair value because the effective yields on these obligations, which include contractual interest rates taken together with other features such as concurrent issuances of warrants and/or embedded conversion options, are comparable to rates of returns for instruments of similar credit risk.
	ASC 820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value:
	Level 1 — quoted prices in active markets for identical assets or liabilities
	Level 2 — quoted prices for similar assets and liabilities in active markets or inputs that are observable
	Level 3 — inputs that are unobservable (for example cash flow modeling inputs based on assumptions)
	We measure derivative liabilities at fair value using the Black-Scholes option pricing model with assumptions that include the fair value of the stock underlying the derivative instrument, the exercise or conversion price of the derivative instrument, the risk free interest rate for a term comparable to the term of the derivative instrument and the volatility rate and dividend yield for our common stock. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant. The Company has not paid dividends to date and does not expect to pay dividends in the foreseeable future due to its substantial accumulated deficit. Accordingly, expected dividends yields are currently zero. Expected volatility is based principally on an analysis of historical volatilities of similarly situated companies in the marketplace for a number of periods that is at least equal to the contractual term or estimated life of the applicable financial instrument.
	We also considered the use of the lattice or binomial models with respect to valuing derivative financial instruments that feature anti-dilution price protection; however, the differences in the results are insignificant due to the low probability of triggering price adjustments in such financial instruments.
	We measure the fair value of all of our derivative liabilities based on Level 3 inputs.
	The following table provides a summary of the changes in fair value of all financial liabilities measured at fair value on a recurring basis using significant unobservable inputs during the year ended June 30, 2014.
	Balance - July 1, 2013		$	3,833,457
	Issuances during the year			2,629,990
	Changes in fair value included in earnings			745,741
	Balance - June 30, 2014		$	7,209,188
Income Tax, Policy [Policy Text Block]	'
	Income taxes. We use the asset and liability method of accounting for income taxes in accordance with ASC Topic 740, “Income Taxes.” Under this method, income tax expense is recognized for the amount of: (i) taxes payable or refundable for the current year and (ii) deferred tax consequences of temporary differences resulting from matters that have been recognized in an entity’s financial statements or tax returns. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the results of operations in the period that includes the enactment date. A valuation allowance is provided to reduce the deferred tax assets reported if, based on the weight of the available positive and negative evidence, it is more likely than not some portion or all of the deferred tax assets will not be realized. Tax returns for the years ended June 30, 2011, 2012 and 2013 are subject to audit by the taxing authorities.
	ASC Topic 740.10.30 clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements and prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. ASC Topic 740.10.40 provides guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosure, and transition. We have no material uncertain tax positions for any of the reporting periods presented.
Earnings Per Share, Policy [Policy Text Block]	'
	Net Loss per Share.  Basic net income or basic net loss per common share is computed by dividing net income available to common shareholders by the weighted average number of common shares outstanding during the periods. Diluted earnings per share give effect to dilutive options, warrants, convertible debt and other potential common stock outstanding during the period. Therefore, in the case of a net loss the impact of the potential common stock resulting from warrants, outstanding stock options, convertible debt, and convertible preferred stock are not included in the computation of diluted loss per share, as the effect would be anti-dilutive. In the case of net income the impact of the potential common stock resulting from these instruments that have intrinsic value are included in the diluted earnings per share. The table sets forth the number of potential shares of common stock that have been excluded from diluted net loss per share.
New Accounting Pronouncements, Policy [Policy Text Block]	'
	New Accounting Pronouncements
	In June 2014, the FASB issued ASU No. 2014-10, Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation.
	The amendments in this Update remove the definition of a development stage entity from the Master Glossary of the Accounting Standards Codification, thereby removing the financial reporting distinction between development stage entities and other reporting entities from U.S. GAAP. In addition, the amendments eliminate the requirements for development stage entities to (1) present inception-to-date information in the statements of income, cash flows, and shareholder equity, (2) label the financial statements as those of a development stage entity, (3) disclose a description of the development stage activities in which the entity is engaged, and (4) disclose in the first year in which the entity is no longer a development stage entity that in prior years it had been in the development stage.
	The amendments also clarify that the guidance in Topic 275, Risks and Uncertainties, is applicable to entities that have not commenced planned principal operations.
	Finally, the amendments remove paragraph 810-10-15-16. Paragraph 810-10-15-16 states that a development stage entity does not meet the condition in paragraph 810-10-15-14(a) to be a variable interest entity if (1) the entity can demonstrate that the equity invested in the legal entity is sufficient to permit it to finance the activities that it is currently engaged in and (2) the entity’s governing documents and contractual arrangements allow additional equity investments.
	The amendments also eliminate an exception provided to development stage entities in Topic 810, Consolidation, for determining whether an entity is a variable interest entity on the basis of the amount of investment equity that is at risk. The amendments to eliminate that exception simplify U.S. GAAP by reducing avoidable complexity in existing accounting literature and improve the relevance of information provided to financial statement users by requiring the application of the same consolidation guidance by all reporting entities. The elimination of the exception may change the consolidation analysis, consolidation decision, and disclosure requirements for a reporting entity that has an interest in an entity in the development stage.
	The amendments related to the elimination of inception-to-date information and the other remaining disclosure requirements of Topic 915 should be applied retrospectively except for the clarification to Topic 275, which shall be applied prospectively. For public business entities, those amendments are effective for annual reporting periods beginning after December 15, 2014, and interim periods therein.
	Early application of each of the amendments is permitted for any annual reporting period or interim period for which the entity’s financial statements have not yet been issued (public business entities) or made available for issuance (other entities). Upon adoption, entities will no longer present or disclose any information required by Topic 915.
	In August 2014, the FASB issued the FASB Accounting Standards Update No. 2014-15 “Presentation of Financial Statements—Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern (“ASU 2014-15”).
	In connection with preparing financial statements for each annual and interim reporting period, an entity’s management should evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the date that the financial statements are issued (or within one year after the date that the financial statements are available to be issued when applicable). Management’s evaluation should be based on relevant conditions and events that are known and reasonably knowable at the date that the financial statements are issued (or at the date that the financial statements are available to be issued when applicable). Substantial doubt about an entity’s ability to continue as a going concern exists when relevant conditions and events, considered in the aggregate, indicate that it is probable that the entity will be unable to meet its obligations as they become due within one year after the date that the financial statements are issued (or available to be issued). The term probable is used consistently with its use in Topic 450, Contingencies.
	When management identifies conditions or events that raise substantial doubt about an entity’s ability to continue as a going concern, management should consider whether its plans that are intended to mitigate those relevant conditions or events will alleviate the substantial doubt. The mitigating effect of management’s plans should be considered only to the extent that (1) it is probable that the plans will be effectively implemented and, if so, (2) it is probable that the plans will mitigate the conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern.
	If conditions or events raise substantial doubt about an entity’s ability to continue as a going concern, but the substantial doubt is alleviated as a result of consideration of management’s plans, the entity should disclose information that enables users of the financial statements to understand all of the following (or refer to similar information disclosed elsewhere in the footnotes):
		a.	Principal conditions or events that raised substantial doubt about the entity’s ability to continue as a going concern (before consideration of management’s plans)
		b.	Management’s evaluation of the significance of those conditions or events in relation to the entity’s ability to meet its obligations
		c.	Management’s plans that alleviated substantial doubt about the entity’s ability to continue as a going concern.
	If conditions or events raise substantial doubt about an entity’s ability to continue as a going concern, and substantial doubt is not alleviated after consideration of management’s plans, an entity should include a statement in the footnotes indicating that there is substantial doubt about the entity’s ability to continue as a going concern within one year after the date that the financial statements are issued (or available to be issued). Additionally, the entity should disclose information that enables users of the financial statements to understand all of the following:
		a.	Principal conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern
		b.	Management’s evaluation of the significance of those conditions or events in relation to the entity’s ability to meet its obligations
		c.	Management’s plans that are intended to mitigate the conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern.
	The amendments are effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter.
	We have elected to adopt early application of Accounting Standards Update No. 2014-10, Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements; we no longer present or disclose inception-to-date information and other remaining disclosure requirements of Topic 915.
	Management does not believe that any other recently issued, but not yet effective accounting pronouncements, when adopted, will have a material effect on the accompanying financial statements.

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Jun. 30, 2014
Accounting Policies [Abstract]	'
Schedule of Derivative Instruments [Table Text Block]	'
	Our derivative instruments were valued using the Black-Scholes option pricing model, using the following assumptions during the year ended June 30, 2014:
	Estimated dividends	None
	Expected volatility	188%
	Risk-free interest rate	1.73%
	Expected term (years)	1.0 - 5.0 years
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	'
	The following table provides a summary of the changes in fair value of all financial liabilities measured at fair value on a recurring basis using significant unobservable inputs during the year ended June 30, 2014.
	Balance - July 1, 2013	$	3,833,457
	Issuances during the year		2,629,990
	Changes in fair value included in earnings		745,741
	Balance - June 30, 2014	$	7,209,188

Convertible_Notes_Payable_Tabl

Convertible Notes Payable (Tables)	12 Months Ended
	Jun. 30, 2014
Debt Disclosure [Abstract]	'
Convertible Debt [Table Text Block]	'
	The following table presents the components of Convertible Notes Payable at June 30, 2014 and June 30, 2013:
				June 30, 2014		June 30, 2013
	(a)	Convertible Notes issued during fiscal year ended June 30, 2010		$	80,000	$	80,000
	(b)	Convertible Notes issued during fiscal year ended June 30, 2011		$	1,100,000	$	1,100,000
	(c)	Convertible Notes issued during fiscal year ended June 30, 2012		$	451,500	$	451,500
	(d)	Convertible Notes issued during fiscal year ended June 30, 2013		$	1,136,000	$	1,136,000
	(e)	Convertible Notes issued during fiscal year ended June 30, 2014		$	527,500
		Balance at End of Period		$	3,295,000	$	2,767,500
		Less debt discount:		$	1,103,345	$	2,180,803
		Convertible Notes Payable, Net		$	2,191,655	$	586,697
		Classified as follows on the accompanying consolidated balance sheets:
		Current portion of Convertible Notes Payable		$	1,464,452	$	645,040
		Long term portion of Convertible Notes Payable		$	727,203	$	586,697
				$	2,191,655	$	1,231,737
Schedule of Maturities of Long-term Debt [Table Text Block]	'
	Convertible Notes Payable are payable as follows:
	Fiscal year ended June 30, 2015	$	1,631,500
	Fiscal year ended June 30, 2016	$	1,136,000
	Fiscal year ended June 30, 2017	$	527,500
	Total	$	3,295,000

Outstanding_Warrants_Tables

Outstanding Warrants (Tables)	12 Months Ended
	Jun. 30, 2014
Derivative Instruments and Hedging Activities Disclosure [Abstract]	'
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	'
	The following table presents the number of Warrants outstanding at year end June 30, 2014 and June 30, 2013. All Warrants have a 5 year term, an exercise price of $0.01 per common share and are exercisable at June 30, 2014. (See Note 12, Subsequent Events)
	Warrants outstanding at June 30, 2012	182,020,022
	Issued	412,750,000
	Exchanged for Series D Preferred Stock	-182,020,022
	Exercised	-46,000,000
	Expired	-
	Balance at the end of period	366,750,000
	Issued	318,750,000
	Exercised	-
	Expired	-
	Warrants outstanding at June 30, 2014	685,500,000

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
	Jun. 30, 2014
Income Tax Disclosure [Abstract]	'
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	'
	The reconciliation of income tax benefit at the U.S. statutory rate of 34% for the years ended June 30, 2014 and 2013 to the Company’s effective tax rate is as follows:
		Years Ended
		June 30, 2014		June 30, 2013
	U.S. federal statutory rate	-34	%	-34	%
	State income tax, net of federal benefit	-6	%	-6	%
	Change in valuation allowance	40	%	40	%
	Income Tax provision (benefit)	0	%	0	%
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	'
	The tax effects of temporary differences that give rise to the Company’s net deferred tax asset as of June 30, 2014 and 2013 are as follows:
		June 30, 2014		June 30, 2013
	Deferred Tax Assets
	Net operating losses	$	8,500,000	$	7,120,000
	Derivative liability		2,883,700		2,146,800
			11,383,700		9,266,800
	Less: Valuation allowance		-8,500,000		-7,120,000
	Net Deferred Tax Assets	$	2,883,700	$	2,146,800
	Deferred Tax Liabilities
	Derivative liability		-2,883,700		-2,146,800
	Total Deferred Tax Liabilities		-2,883,700		-2,146,800
	Net Deferred taxes		-		-

StockBased_Compensation_Plans_

Stock-Based Compensation Plans (Tables)	12 Months Ended
	Jun. 30, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	'
	A summary of the transaction in the 2006 Stock Plan is as follows:
			Weighted		Instrinisic		Weighted
			Average		value		Average
			Exercise Price				Remaining
							Contractual
							Life
	Options outstanding at June 30, 2012	213,243	$	34.87	$	-		3.35
	Granted	-	$	-				-
	Cancelled/Forfeited	-	$	-		-
	Expired	-	$	-
	Balance at the end of period	213,243	$	34.87		-		3.35
	Options excercisable at June 30, 2013	213,243	$	34.87		-		3.35
	Expired	201,243	$	34.87
	Balance at June 30, 2014	12,000	$	0.22				2
	Options vested or expected to vest	12,000	$	0.22		-		2

Business_Description_and_Going1

Business Description and Going Concern (Details Textual) (USD $)	12 Months Ended		110 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2012
Business Description And Going Concern [Line Items]	'	'	'	'
License fees	$0	$0	$10,516,667	'
Cash and cash equivalents	0	5,138	0	2,307
Working Capital Deficit	-27,435,588	'	-27,435,588	'
Development Stage Enterprise, Deficit Accumulated During Development Stage	98,943,510	83,891,966	98,943,510	'
Operating Income (Loss)	-1,137,240	-4,347,686	'	'
Net Cash Provided by (Used in) Operating Activities, Continuing Operations	-632,638	-1,130,669	'	'
Total Capital Deficiency	-28,160,791	-13,548,426	-28,160,791	-11,079,928
Common Stock, Par Or Stated Value Per Share	$0.00	$0.00	$0.00	'
Notional Proceeds From Milestone Payments	120,000,000	'	'	'
Investor [Member]	'	'	'	'
Business Description And Going Concern [Line Items]	'	'	'	'
Issuance Of Warrants	2,400,000,000	'	'	'
Common Stock, Par Or Stated Value Per Share	$0.00	'	$0.00	'
Series F Convertible Preferred Stock [Member] | Investor [Member]	'	'	'	'
Business Description And Going Concern [Line Items]	'	'	'	'
Stock Issued During Period, Shares, New Issues	1,200	'	'	'
Proceeds from Issuance of Convertible Preferred Stock	$1,200,000	'	'	'

Summary_of_Significant_Account3

Summary of Significant Accounting Policies (Details)	12 Months Ended
	Jun. 30, 2014
Derivatives, Fair Value [Line Items]	'
Estimated dividends	'None
Expected volatility	188.00%
Risk-free interest rate	1.73%
Minimum [Member]	'
Derivatives, Fair Value [Line Items]	'
Expected term (years)	'1 year
Maximum [Member]	'
Derivatives, Fair Value [Line Items]	'
Expected term (years)	'5 years

Summary_of_Significant_Account4

Summary of Significant Accounting Policies (Details 1) (USD $)	12 Months Ended
	Jun. 30, 2014
Derivatives, Fair Value [Line Items]	'
Balance - July 1, 2013	$3,833,457
Issuances during the year	2,629,990
Changes in fair value included in earnings	745,741
Balance - June 30, 2014	$7,209,188

Summary_of_Significant_Account5

Summary of Significant Accounting Policies (Details Textual) (USD $)	12 Months Ended
	Jun. 30, 2014	Jun. 30, 2013
Accounting Policies [Line Items]	'	'
Derivative, Gain (Loss) on Derivative, Net, Total	($745,741)	$2,549,892
Derivative Liabilities	7,200,000	2,600,000
Research and Development Expense	$82,620	$222,300

Material_Agreements_Details_Te

Material Agreements (Details Textual) (USD $)

12 Months Ended

110 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Sep. 30, 2011

Jun. 30, 2005

Sep. 30, 2011

Jun. 30, 2014

Aug. 31, 2008

31-May-08

Dec. 31, 2008

Oct. 31, 2008

Apr. 30, 2009

Oct. 31, 2008

Jun. 30, 2014

Research and License Agreements [Member]

Research and License Agreements [Member]

Viropharma License Agreements [Member]

Beta Amyloid Purchase and Sale Agreement [Member]

Elan and Wyeth License Agreement [Member]

Elan and Wyeth License Agreement [Member]

Antisenilin Option and License Agreement [Member]

Antisenilin Option and License Agreement [Member]

Gsk Option and License Agreement [Member]

Gsk Option and License Agreement [Member]

Northwestern University License Agreement [Member]

Material Agreements [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Future Payments For Clinical Development

'

'

'

'

$3,000,000

'

'

'

'

'

'

'

'

$700,000

Licenses Revenue

0

0

10,516,667

'

'

6,500,000

'

1,000,000

1,000,000

'

'

'

'

'

License Fee Payment

'

'

'

650,000

'

'

'

'

'

'

'

'

'

'

Payments For Clinical Development

'

'

'

'

'

'

2,125,000

'

'

'

'

'

'

'

Research Expenses Abandonment

'

'

'

'

'

'

'

'

50,000

'

'

'

'

'

Non Refundable Fee

'

'

'

'

'

'

'

'

'

'

500,000

'

'

'

Adjustments to Additional Paid in Capital, Share-based Compensation and Exercise of Stock Options

'

'

'

'

'

'

'

'

'

1,550,000

2,000,000

'

'

'

Additional Grant Received Licensed Patent

'

'

'

'

'

'

'

'

'

'

$2,000,000

$2,000,000

$2,000,000

'

Revenue Recognition, Milestone Method, Milestone

'

'

'

'

'

'120 million

'

'

'

'

'

'

'

'

License Agreement Termination Description

'

'

'

'

'

'at any time upon ninety (90) days prior written notice to the Company

'

'

'

'

'

'

'

'

Convertible_Notes_Payable_Deta

Convertible Notes Payable (Details) (USD $)	Jun. 30, 2014		Jun. 30, 2013
Debt Instrument [Line Items]	'		'
Long-term Debt, Gross	$3,295,000		$2,767,500
Less debt discount:	1,103,345		2,180,803
Convertible Notes Payable, Noncurrent	727,203		586,697
Current portion of Convertible Notes Payable	1,464,452		645,040
Long term portion of Convertible Notes Payable	727,203		586,697
Convertible Notes Payable	2,191,655		1,231,737
Convertible Notes issued during fiscal year ended June 30, 2010 [Member]	'		'
Debt Instrument [Line Items]	'		'
Long-term Debt, Gross	80,000	[1]	80,000	[1]
Convertible Notes issued during fiscal year ended June 30, 2011 [Member]	'		'
Debt Instrument [Line Items]	'		'
Long-term Debt, Gross	1,100,000	[2]	1,100,000	[2]
Convertible Notes issued during fiscal year ended June 30, 2012 [Member]	'		'
Debt Instrument [Line Items]	'		'
Long-term Debt, Gross	451,500	[3]	451,500	[3]
Convertible Notes issued during fiscal year ended June 30, 2013 [Member]	'		'
Debt Instrument [Line Items]	'		'
Long-term Debt, Gross	1,136,000	[4]	1,136,000	[4]
Convertible Notes issued during fiscal year ended June 30, 2014 [Member]	'		'
Debt Instrument [Line Items]	'		'
Long-term Debt, Gross	$527,500	[5]	'	[5]
[1]	During fiscal year ended June 30, 2010, we issued Convertible Promissory Notes of $730,000, which carry interest at 14% annually, mature three years from the issue date and are convertible into the Company's common shares at a conversion price of $0.01 per share. As of June 30, 2014, Notes of $80,000 were in default. These Notes were repaid in July 2014.
[2]	During fiscal year ended June 30, 2011, we issued Convertible Promissory Notes of $1,100,000, which carry interest at 14% annually, mature three years from the issue date and are convertible into the Company's common shares at a conversion price of $0.01 per share. As of June 30, 2014, these Notes were in default. Notes of $220,000 were repaid in July 2014.
[3]	During fiscal year ended June 30, 2012, we issued Convertible Promissory Notes of $451,500, which carry interest at 14% annually, mature three years from the issue date and are convertible into the Company's common shares at a conversion price of $0.01 per share.
[4]	During fiscal year ended June 30, 2013, we issued Convertible Promissory Notes of $1,136,000, which carry interest at 14% annually, mature three years from the issue date and are convertible into the Company's common shares at a conversion price of $0.01 per share.
[5]	During fiscal year ended June 30, 2014, we issued Convertible Promissory Notes with an aggregate principal amount of $527,500. These Notes carry interest at 14% annually (payable in arrears), mature three years from the issue date and are convertible into the Company's common shares at a conversion price of $0.01 per share.

Convertible_Notes_Payable_Deta1

Convertible Notes Payable (Details 1) (USD $)	Jun. 30, 2014	Jun. 30, 2013
Debt Instrument [Line Items]	'	'
Fiscal year ended June 30, 2015	$1,631,500	'
Fiscal year ended June 30, 2016	1,136,000	'
Fiscal year ended June 30, 2017	527,500	'
Total	$3,295,000	$2,767,500

Convertible_Notes_Payable_Deta2

Convertible Notes Payable (Details Textual) (USD $)	12 Months Ended
	Jun. 30, 2014
Convertible Notes issued during fiscal year ended June 30, 2010 [Member]	'
Debt Instrument [Line Items]	'
Debt Instrument, Face Amount	$730,000
Debt Instrument, Interest Rate, Stated Percentage	14.00%
Debt Instrument, Maturity Date, Description	'mature three years from the issue date
Debt Instrument, Convertible, Conversion Price	$0.01
Debt Instrument, Debt Default, Amount	80,000
Convertible Notes issued during fiscal year ended June 30, 2011 [Member]	'
Debt Instrument [Line Items]	'
Debt Instrument, Face Amount	1,100,000
Debt Instrument, Interest Rate, Stated Percentage	14.00%
Debt Instrument, Maturity Date, Description	'mature three years from the issue date
Debt Instrument, Convertible, Conversion Price	$0.01
Repayments of Debt	220,000
Convertible Notes issued during fiscal year ended June 30, 2012 [Member]	'
Debt Instrument [Line Items]	'
Debt Instrument, Face Amount	451,500
Debt Instrument, Interest Rate, Stated Percentage	14.00%
Debt Instrument, Maturity Date, Description	'mature three years from the issue date
Debt Instrument, Convertible, Conversion Price	$0.01
Convertible Notes issued during fiscal year ended June 30, 2013 [Member]	'
Debt Instrument [Line Items]	'
Debt Instrument, Face Amount	1,136,000
Debt Instrument, Interest Rate, Stated Percentage	14.00%
Debt Instrument, Maturity Date, Description	'mature three years from the issue date
Debt Instrument, Convertible, Conversion Price	$0.01
Convertible Notes issued during fiscal year ended June 30, 2014 [Member]	'
Debt Instrument [Line Items]	'
Debt Instrument, Face Amount	$527,500
Debt Instrument, Interest Rate, Stated Percentage	14.00%
Debt Instrument, Maturity Date, Description	'mature three years from the issue date
Debt Instrument, Convertible, Conversion Price	$0.01

Convertible_Preferred_Stock_De

Convertible Preferred Stock (Details Textual) (USD $)	12 Months Ended
	Jun. 30, 2014	Jun. 30, 2013
Series B Convertible Preferred Stock [Member]	'	'
Convertible Preferred Stock And Derivative Liability [Line Items]	'	'
Preferred Stock, Dividend Rate, Percentage	6.00%	'
Preferred Stock Initial Conversion Price Per Share	$1.50	'
Convertible Preferred Stock, Total Shares Issued Upon Conversion	11.67	'
Preferred Stock Stated Value Per Share	$17.50	'
Series C Convertible Preferred Stock [Member]	'	'
Convertible Preferred Stock And Derivative Liability [Line Items]	'	'
Preferred Stock, Dividend Rate, Percentage	14.00%	'
Preferred Stock Initial Conversion Price Per Share	$0.01	'
Convertible Preferred Stock, Total Shares Issued Upon Conversion	100,000	'
Preferred Stock Stated Value Per Share	$1,000	'
Conversion of Stock, Shares Converted	54,214,500	37,000,000
Conversion of Stock, Shares Issued	543	570
Series D Convertible Preferred Stock [Member]	'	'
Convertible Preferred Stock And Derivative Liability [Line Items]	'	'
Preferred Stock, Dividend Rate, Percentage	8.00%	'
Preferred Stock Initial Conversion Price Per Share	$0.01	'
Convertible Preferred Stock, Total Shares Issued Upon Conversion	100,000	'
Preferred Stock Stated Value Per Share	$1,000	'
Conversion of Stock, Shares Converted	84,098,622	25,000,000
Conversion of Stock, Shares Issued	841	250
Series E Convertible Preferred Stock [Member]	'	'
Convertible Preferred Stock And Derivative Liability [Line Items]	'	'
Preferred Stock, Dividend Rate, Percentage	8.00%	'
Preferred Stock Initial Conversion Price Per Share	$0.01	'
Convertible Preferred Stock, Total Shares Issued Upon Conversion	100,000	'
Preferred Stock Stated Value Per Share	$1,000	'

Outstanding_Warrants_Details

Outstanding Warrants (Details)	12 Months Ended
	Jun. 30, 2014	Jun. 30, 2013
Class of Warrant or Right [Line Items]	'	'
Options outstanding at beginning of period	213,243	213,243
Issued	'	0
Exchanged for Series D Preferred Stock	'	0
Expired	201,243	0
Balance at the end of period	12,000	213,243
Warrant [Member]	'	'
Class of Warrant or Right [Line Items]	'	'
Options outstanding at beginning of period	366,750,000	182,020,022
Issued	318,750,000	412,750,000
Exchanged for Series D Preferred Stock	'	-182,020,022
Exercised	0	-46,000,000
Expired	0	0
Balance at the end of period	685,500,000	366,750,000

Outstanding_Warrants_Details_T

Outstanding Warrants (Details Textual) (USD $)	12 Months Ended
	Jun. 30, 2014
Class of Warrant or Right [Line Items]	'
Warrants Expiration, Term	'5 years
Class of Warrant or Right, Exercise Price of Warrants or Rights	$0.01

Income_Taxes_Details

Income Taxes (Details)	12 Months Ended
	Jun. 30, 2014	Jun. 30, 2013
Income Taxes [Line Items]	'	'
U.S. federal statutory rate	-34.00%	-34.00%
State income tax, net of federal benefit	-6.00%	-6.00%
Change in valuation allowance	40.00%	40.00%
Income Tax provision (benefit)	0.00%	0.00%

Income_Taxes_Details_1

Income Taxes (Details 1) (USD $)	Jun. 30, 2014	Jun. 30, 2013
Deferred Tax Assets	'	'
Net operating losses	$8,500,000	$7,120,000
Derivative liability	2,883,700	2,146,800
Deferred Tax Assets, Gross, Total	11,383,700	9,266,800
Less: Valuation allowance	-8,500,000	-7,120,000
Net Deferred Tax Assets	2,883,700	2,146,800
Deferred Tax Liabilities	'	'
Derivative liability	-2,883,700	-2,146,800
Total Deferred Tax Liabilities	-2,883,700	-2,146,800
Net Deferred taxes	$0	$0

Income_Taxes_Details_Textual

Income Taxes (Details Textual) (USD $)	12 Months Ended
	Jun. 30, 2014	Jun. 30, 2013
Income Taxes [Line Items]	'	'
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	-34.00%	-34.00%
Deferred Tax Assets, Operating Loss Carryforwards, State and Local	$21,000,000	'
Utilization Of Net Operating Losses Description	'Utilization of the NOLs may be subject to limitation under Internal Revenue Code Section 382 should there be a greater than 50% ownership change as determined under regulations.	'

Capital_Deficiency_Details_Tex

Capital Deficiency (Details Textual) (USD $)	1 Months Ended		12 Months Ended
	Oct. 31, 2013	Mar. 31, 2013	Jun. 30, 2014	Jun. 30, 2013
Schedule of Equity Method Investments [Line Items]	'	'	'	'
Debt Conversion, Converted Instrument, Amount	'	'	$131,929	'
Series C Convertible Preferred Stock [Member]	'	'	'	'
Schedule of Equity Method Investments [Line Items]	'	'	'	'
Convertible Preferred Stock, Shares Issued Upon Conversion	'	'	100,000	'
Series D Convertible Preferred Stock [Member]	'	'	'	'
Schedule of Equity Method Investments [Line Items]	'	'	'	'
Convertible Preferred Stock, Shares Issued Upon Conversion	'	'	100,000	'
Series B Convertible Preferred Stock [Member]	'	'	'	'
Schedule of Equity Method Investments [Line Items]	'	'	'	'
Convertible Preferred Stock, Shares Issued Upon Conversion	'	'	11.67	'
Convertible Preferred Stock [Member]	'	'	'	'
Schedule of Equity Method Investments [Line Items]	'	'	'	'
Convertible Preferred Stock, Shares Issued Upon Conversion	'	'	138,313,122	62,000,000
Common Stock [Member]	'	'	'	'
Schedule of Equity Method Investments [Line Items]	'	'	'	'
Stock Issued During Period, Shares, Issued for Services	'	'	34,500,000	17,250,000
Stock Issued During Period Shares Cashless Exercise Of Warrants	'	46,000,000	'	29,525,879
Convertible Preferred Stock, Shares Issued Upon Conversion	'	29,525,879	'	'
Debt Conversion, Converted Instrument, Shares Issued	13,183,055	'	13,183,055	'
Debt Conversion, Converted Instrument, Amount	'	'	13,183	'
Common Stock [Member] | Charitable Donations [Member]	'	'	'	'
Schedule of Equity Method Investments [Line Items]	'	'	'	'
Stock Issued During Period, Value, Other	'	'	$4,500,000	'

Commitments_and_Contingencies_

Commitments and Contingencies (Details Textual) (USD $)	1 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2012
Loss Contingencies [Line Items]	'
Loss Contingency, Damages Sought, Value	$2

StockBased_Compensation_Plans_1

Stock-Based Compensation Plans (Details) (USD $)	12 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Options outstanding at beginning of period	213,243	213,243	'
Granted	'	0	'
Cancelled/Forfeited	'	0	'
Expired	201,243	0	'
Balance at the end of period	12,000	213,243	213,243
Options excercisable - Options	213,243	'	'
Options vested or expected to vest	12,000	'	'
Options outstanding - Weighted Average Exercise Price	$34.87	$34.87	'
Granted - Weighted Average Exercise Price	'	$0	'
Cancelled/Forfeited - Weighted Average Exercise Price	'	$0	'
Expired - Weighted Average Exercise Price	$34.87	$0	'
Balance at the end of period - weighted Average Exercise Price	$0.22	$34.87	$34.87
Options excercisable - Weighted Average Exercise Price	$34.87	'	'
Options vested or expected to vest - Weighted Average Exercise Price	$0.22	'	'
Options outstanding - Instrinisic value	$0	$0	'
Cancelled/Forfeited - Intrinsic value	'	0	'
Balance at the end of period - Intrinsic value	'	0	0
Options excercisable - Intrinsic value	0	'	'
Options vested or expected to vest - Intrinsic value	$0	'	'
Options outstanding - Weighted Average Remaining Contractual Life	'2 years	'3 years 4 months 6 days	'3 years 4 months 6 days
Granted - Weighted Average Remaining Contractual Life	'	'0 years	'
Options excercisable - Weighted Average Remaining Contractual Life	'	'3 years 4 months 6 days	'
Options vested or expected to vest - Weighted Average Remaining Contractual Life	'2 years	'	'

StockBased_Compensation_Plans_2

Stock-Based Compensation Plans (Details Textual) (USD $)	12 Months Ended			1 Months Ended	12 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2007	Jun. 30, 2011	Jun. 30, 2011	Jun. 30, 2009
				Consultant [Member]	Consultant [Member]	Consultant [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant	228,000	26,757	240,000	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	'	0	'	10,000	2,000	500
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price	'	$0	'	$0.10	$0.83	$17.50
Share-based Compensation	$0	$0	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	'	'	'	'12 months	'12 months	'12 months
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Date	'	'	'	13-Jun-16	31-Aug-15	30-Mar-14

Subsequent_Events_Details_Text

Subsequent Events (Details Textual) (USD $)

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2013

Sep. 30, 2014

Aug. 31, 2014

Jul. 31, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2014

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Series C Convertible Preferred Stock [Member]

Series C Convertible Preferred Stock [Member]

Series C Convertible Preferred Stock [Member]

Series C Convertible Preferred Stock [Member]

Series C Convertible Preferred Stock [Member]

Series C Convertible Preferred Stock [Member]

Series D Convertible Preferred Stock [Member]

Series D Convertible Preferred Stock [Member]

Series D Convertible Preferred Stock [Member]

Series F Preferred Stock [Member]

Convertible Promissory Notes [Member]

Convertible Promissory Notes [Member]

Convertible Promissory Notes [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Maximum [Member]

Minimum [Member]

Subsequent Event [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Convertible Preferred Stock Conversion Price Per Share

'

'

'

'

'

'

'

'

'

'

'

$0.01

'

'

$0.01

$0.00

Convertible Preferred Stock, Total Shares Issued Upon Conversion

'

'

'

'

'

'

100,000

'

65,000,000

84,000,000

65,000,000

'

100,000

'

'

'

Stock Issued During Period, Shares, New Issues

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,200

Common Stock, Par or Stated Value Per Share

$0.00

$0.00

$0.00

'

'

'

'

'

'

'

'

'

'

'

'

'

Class of Warrant or Right, Number of Securities Called by Warrants or Rights

'

'

2,400,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Preferred Stock, Par or Stated Value Per Share

'

'

'

'

'

'

$0.00

$0.00

'

'

'

'

$0.00

$0.00

'

$1,000

Preferred Stock, Dividend Rate, Percentage

'

'

'

'

'

'

14.00%

'

'

'

'

'

8.00%

'

'

8.00%

Class Of Warrant Or Rights Term From Which Warrants Or Rights Exercisable

'

'

'5 years

'

'

'

'

'

'

'

'

'

'

'

'

'

Class of Warrant or Right, Exercise Price of Warrants or Rights

$0.01

'

$0.00

'

'

'

'

'

'

'

'

'

'

'

'

'

Registration Rights Agreement Terms

'

'

'Under the terms of the Registration Rights Agreement, the Company is required to file a Registration Statement with the SEC within 115 days after the Closing Date and declared effective by the SEC not later than 180 days from the Closing Date

'

'

'

'

'

'

'

'

'

'

'

'

'

Convertible Preferred Stock, Settlement Terms

'

'

'Waive the covenant of the Company to refrain from issuing any shares of capital stock senior to or on parity with each series of preferred stock, and to reserve and keep available unissued shares of Common Stock for the purpose of effecting the conversion of the shares of each series of preferred stock for a period of six (6) months from the Closing Date

'

'

'

'

'

'

'

'

'

'

'

'

'

Class of Warrant or Right, Title of Security Warrants or Rights Outstanding

'

'

'(i) eliminate the ratchet provision for subsequent issuances of securities going forward, (ii) waive the covenant of the Company to reserve and keep available unissued shares of Common Stock for the purpose of effecting the conversion of the Outstanding Warrants for a period of six (6) months from the Closing Date and (iii) provide that the exercise price of the Outstanding Warrants be the effective price per share, upon cashless exercise, shall be 50% of the fair market value of the Common Stock on the date of exercise.

'

'

'

'

'

'

'

'

'

'

'

'

'

Repayments of Notes Payable

'

'

$300,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Convertible Preferred Stock Purchase Consideration

'

'

100

'

'

'

'

'

'

'

'

'

'

'

'

'

Stockholders' Equity, Reverse Stock Split

'

'

'every two hundred and fifty (250) shares of common stock issued and outstanding, two hundred and fifty (250) shares of common stock shall be combined and converted into one (1) share of common stock.

'

'

'

'

'

'

'

'

'

'

'

'

'

Payments for Repurchase of Convertible Preferred Stock

'

'

16,750,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt Instrument, Convertible, Terms of Conversion Feature

'

'

'

'(i) eliminate the ratchet provision for subsequent issuances of securities going forward, (ii) waive the covenant of the Company to reserve and keep available unissued shares of Common Stock for the purpose of effecting the conversion of the Promissory Notes and (iii) provide that the conversion price shall be $0.005, but for two of the holders holding an aggregate of $845,000 principal amount of Promissory Notes, the conversion price shall be equal to $0.00032 per share of Common Stock and $0.00055 per share of Common Stock.

'

'

'

'

'

'

'

'

'

'

'

'

Debt Instrument, Convertible, Conversion Price

'

'

'

$0.01

$0.00

$0.00

'

'

'

'

'

'

'

'

'

'

Debt Instrument, Face Amount

'

'

'

$845,000

'

'

'

'

'

'

'

'

'

'

'

'